

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number
WO 02/085402 A1

(51) International Patent Classification⁷: A61K 38/00,
38/16

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US02/12891

(22) International Filing Date: 24 April 2002 (24.04.2002)

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:
60/286,240 24 April 2001 (24.04.2001) US

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicant: THE GENERAL HOSPITAL CORPORATION [US/US]; 32 Fruit Street, Boston, MA 02114 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventor: PODOLSKY, Daniel, K.; 157 Edmunds Road, Wellesley Hills, MA 02181 (US).

(74) Agent: CLARK, Paul, T.; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,



WO 02/085402 A1

(54) Title: METHODS AND COMPOSITIONS FOR TREATING ORAL AND EOSOPHAGEAL LESIONS

(57) Abstract: The invention features methods and compositions for treating or preventing lesions of the upper elementary canal, particularly oral aphthous or mucositis lesions. Intestinal trefoil peptides are administered in effective concentrations either alone or in combination with different therapeutic agents.

5

METHODS AND COMPOSITIONS FOR TREATING ORAL AND ESOPHAGEAL LESIONS

Field of the Invention

This invention provides methods and compositions for treating lesions of
10 the upper alimentary canal including the oral cavity and esophagus.

Background of the Invention

Oral mucositis is the destruction of the oral mucosal epithelium which
results in erythema, ulcerations, and pain in the oral cavity. Mucositis often arises
15 as a complication of antineoplastic therapy such as cancer chemotherapy or
radiotherapy. The painful ulcerative lesions of mucositis can cause patients to
restrict their oral intake of food and liquids; as a result, they lose weight and
suffer from dehydration. Severe mucositis can necessitate the de-escalation or the
complete interruption of anti-neoplastic therapy. Chemotherapy or radiotherapy
20 can also disrupt mucosal epithelium more distally in the gastrointestinal tract
including the esophagus, stomach, and small and large intestines, resulting in pain
and organ dysfunction (i.e., diarrhea).

The mucositis lesions are also sites of secondary infections, acting as
portals of entry for endogenous oral microorganisms; a particularly serious
25 concern in patients who are immunocompromised. Mucositis is therefore a
significant risk factor for chronic debilitating local infections (e.g. yeast
(*Candida*) infections) as well as life-threatening systemic infection (septicemia).
Patients with mucositis and neutropenia have a relative risk of septicemia that is
at least four times greater than that of individuals without mucositis.

30 Aphthous ulcers of the mouth (or aphthous stomatitis) are a common and
painful problem; approximately 10% of the population suffers from these mouth
sores at one time or another. The cause of outbreaks of aphthous sores are not

well understood, although they tend to be associated with stress and minor injury to the inside of the mouth. No satisfactory treatments are available, although topical application of steroids provides relief for some patients.

5

Summary of the Invention

This invention features a method for treating a lesion of the upper alimentary canal in a mammal by administering to the mammal a therapeutically effective amount of an intestinal trefoil peptide. Preferably, the mammal is a human. In preferred embodiments, the intestinal trefoil peptide is spasmolytic polypeptide (SP), pS2, or intestinal trefoil factor (ITF). More preferably, the intestinal trefoil peptide is ITF.

Lesions of the upper alimentary canal such as mucositis, aphthous stomatitis, and gingivitis can be treated by the methods of this invention. Additionally, lesions of the upper alimentary canal that result from antineoplastic therapy (i.e., chemotherapy or radiotherapy), Behcet's Disease, biopsy, surgery, tumor resection, thermal or chemical burns, tooth extraction, trauma from any cause, or lesions caused by microbial (i.e., bacterial, viral, or fungal) infection are also amenable to treatment.

In preferred embodiments, the patient is also administered a second therapeutic agent. Preferred second therapeutic agents include anti-inflammatory agents, antibacterial agents (i.e., penicillins, cephalosporins, tetracyclines, or aminoglycosides), antifungal agents (i.e., nystatin or amphotericin B), antiviral agents (i.e., acyclovir), topical antiseptics (i.e., povidone-iodine), analgesics (i.e., lidocaine or benzocaine), or steroids (i.e., triamcinolone or hydrocortisone). Preferably, the second therapeutic agent is administered within 3 days, 1 day, 12 hours, 1 hour, or simultaneously with the intestinal trefoil peptide. The second therapeutic agent can be present in the same pharmaceutical composition as the intestinal trefoil peptide.

The invention also features pharmaceutical compositions suitable for delivering an intestinal trefoil peptide to the upper alimentary canal. Preferably, the pharmaceutical composition is an oral spray, an oral rinse (mouthwash), an ointment, a paste, a cream, a gel, chewing gum, a chewable tablet, a lozenge, or a 5 bioerodabile film. In one embodiment, the pharmaceutical compositions use bioerodabile microspheres to encapsulate one or more of the therapeutic agents. In preferred embodiments of an oral spray, rinse, ointment, paste, gel, or bioerodabile film, a mucoadhesive or viscosity-enhancing agent is present.

In other preferred embodiments, the intestinal trefoil peptide of the 10 pharmaceutical composition is SP, pS2, or ITF. More preferably, the intestinal trefoil peptide is ITF. In other preferred embodiments, the pharmaceutical composition further contains a second therapeutic. Preferred second therapeutic agents include anti-inflammatory agents, antibacterial agents (i.e., penicillins, cephalosporins, tetracyclines, or aminoglycosides), antifungal agents (i.e., nystatin 15 or amphotericin B), antiviral agents (i.e., acyclovir), topical antiseptics (i.e., povidone-iodine), analgesics (i.e., lidocaine or benzocaine), or steroids (i.e., triamcinolone or hydrocortisone).

By "intestinal trefoil peptide" is meant all mammalian homologs of human spasmolytic polypeptide (SP; also known as TFF2), human pS2 (also known as 20 TFF1) and human intestinal trefoil factor (ITF; also known as TFF3), and biologically active fragments thereof. Homologs of the trefoil peptides have, preferably, 70% amino acid identity to the human sequence, more preferably 85% identity, most preferably 95%, or even 99% sequence identity. The length of comparison sequences will generally be at least about 10 amino acid residues, 25 usually at least 20 amino acid residues, more usually at least 30 amino acid residues, typically at least 45 amino acid residues, and preferably more than 60 amino acid residues.

The term "fragment" is meant to include polypeptides that are truncations or deletions of SP, pS2 and ITF. Preferably, the fragments have 70% amino acid 30 identity to the corresponding regions of the human polypeptide sequence. More

preferably, the fragments are 85% identical, most preferably 95%, or even 99% identical to the human polypeptide sequence to which they correspond. The length of comparison sequences will generally be at least about 10 amino acid residues, usually at least 20 amino acid residues, more usually at least 30 amino acid residues, typically at least 45 amino acid residues, and preferably more than 60 amino acid residues.

Preferable fragments contain four cysteine residues in any positions which correspond to the cysteines at positions 25, 35, 45, 50, 51, 62, or 71, of human ITF (Figure 1), or positions 31, 41, 51, 56, 57, 68, and 82 of human pS2 (Figure 2). More preferably, fragments contain five cysteine residues at these positions. Most preferably, six, or even all seven cysteines are present.

Fragments of SP are meant to include truncations or deletions and preferably have 70% sequence identity to the corresponding human SP polypeptide sequence (Figure 3). More preferably, the fragments are 85% identical, most preferably 95%, or even 99% identical to the human polypeptide sequence. Preferably, active fragments contain at least four cysteine residues which correspond to positions 6, 8, 19, 29, 34, 35, 46, 58, 68, 78, 83, 84, 95, and 104 in the human SP polypeptide. More preferably, fragments contain six cysteines which correspond to these positions. Even more preferable are fragments that contain eight cysteines. Most preferable are fragments that contain cysteines at ten, twelve, or even, all fourteen positions.

It is recognized in the art that one function of the identified cysteine residues is to impart the characteristic three-loop (trefoil) structure to the protein. Accordingly, preferred fragments of ITF and pS2 have a least one loop structure, more preferably, the fragments have two loop structures, and most preferably, they have three loop structures. It is equally well recognized that the native SP polypeptide has a six loop confirmation. Preferable fragments contain at least two of these loop structures, more preferably, four loop structures are conserved, and most preferably, five, or even all six loop structures are present.

By "co-formulated" is meant any single pharmaceutical composition which contains two or more therapeutic or biologically active agents.

By "pharmaceutical preparation" or "pharmaceutical composition" is meant any composition which contains at least one therapeutically or biologically active agent and is suitable for administration to a patient. For the purposes of this invention, pharmaceutical compositions suitable for delivering a therapeutic to the upper alimentary canal include, but are not limited to solutions and suspensions delivered either as an oral spray or rinse, pastes, gels, chewable tablets, sublingual, gingival, or buccal wafers and films, chewing gum, lozenges, and other compositions designed to be retained in the mouth for an extended period of time. Any of these formulations can be prepared by well known and accepted methods of art. See, for example, Remington: The Science and Practice of Pharmacy, 19th edition, (ed. AR Gennaro), Mack Publishing Co., Easton, PA, 1995.

By "microsphere" is meant a bioerodable polymeric pharmaceutical delivery device having a diameter of 5-100 μm and a hollow central core suitable for encapsulation of the therapeutic agent. Typically, the therapeutic agent is encapsulated at the time of microsphere formulation.

By "therapeutically effective amount" is meant an amount sufficient to provide medical benefit. When administering trefoil peptides to a human patient according to the methods described herein, a therapeutically effective amount is usually about 0.1-1000 mg of intestinal trefoil peptide per day. Preferably, the patient receives, 10 mg, 100 mg, 250 mg, or 750 mg of intestinal trefoil peptide each day. The total daily does can be divided into multiple individual doses.

By "upper alimentary canal" is meant the portion of the digestive system proximal to the cardiac sphincter (cardioesophageal sphincter) of the stomach. Specifically, the upper alimentary canal is meant to include the oral cavity and associated structures (e.g., the tongue, gingival and sublingual tissues, and the hard and soft palates) and the esophagus.

By "biologically active," when referring to an intestinal trefoil peptide, fragment, or homolog is meant any polypeptide that exhibits an activity common to its related, naturally occurring family member, and that the activity is common to the family of naturally occurring intestinal trefoil peptides. An example of a 5 biological activity common to the family of trefoil peptides is the ability to alter gastrointestinal motility in a mammal.

By "isolated DNA" is meant DNA that is free of the genes which, in the naturally-occurring genome of the organism from which the given DNA is derived, flank the DNA. Thus, the term "isolated DNA" encompasses, for 10 example, cDNA, cloned genomic DNA, and synthetic DNA.

By "treating" is meant administering a pharmaceutical composition for prophylactic and/or therapeutic purposes. The active ingredients of the pharmaceutical composition can treat the primary indication (i.e., epithelial lesion) or secondary symptoms (e.g., concomitant infection, pain, or 15 inflammation).

By "analgesic" is meant an agent which relieves pain by elevating the pain threshold without significantly disturbing the consciousness of the patient.

By "antimicrobial agent" is meant any compound that alters the growth of bacteria or fungi cells, or viruses whereby growth is prevented, stabilized, or 20 inhibited, or wherein the microbes are killed. In other words, the antimicrobial agents can be microbiocidal or microbiostatic.

By "thermal burn" is meant injury to or destruction of at least the epithelial cell layer caused by exposure to excessive temperature. Thermal burns of the upper alimentary canal are usually caused by ingestion of overly-heated foods and 25 liquids, or inhalation of super-heated air. Thermal burns are meant to include, but are not limited to, burns classified as first degree, second degree, and third degree burns.

By "chemical burn" is meant injury to or destruction of at least the epithelial cell layer caused by exposure to noxious chemicals. Typically, 30 chemical exposures of the upper alimentary canal are caused by inhalation or

ingestion.

By "antineoplastic therapy" is meant any treatment regimen used to treat cancer. Typical antineoplastic therapies include chemotherapy and radiation therapy.

5

Brief Description of Drawings

Figure 1 is the amino acid sequence of a human intestinal trefoil factor (ITF; Accession No. BAA95531; SEQ ID NO: 1).

10 Figure 2 is the amino acid sequence of a human pS2 protein (Accession No. NP_003216; SEQ ID NO: 2).

Figure 3 is the amino acid sequence of human spasmolytic polypeptide (SP; Accession No. 1909187A; SEQ ID NO:3).

Figure 4 is a cDNA sequence encoding a human intestinal trefoil factor (SEQ ID NO: 4).

15 Figure 5 is a cDNA sequence encoding a human pS2 protein (SEQ ID NO: 5).

Figure 6 is a cDNA sequence encoding a human spasmolytic polypeptide (SEQ ID NO: 6).

20 Figure 7 is the nucleotide sequence of a gene encoding human intestinal trefoil factor (locus 10280533:52117-55412; SEQ ID NO: 7).

Figure 8 is the nucleotide sequence of a gene encoding human pS2 protein (locus 10280533:16511-21132; SEQ ID NO: 8).

Figure 9 is the nucleotide sequence of a gene encoding human spasmolytic polypeptide (locus 10280533:957-5208; SEQ ID NO: 9).

25

Detailed Description

The invention provides methods and compositions useful for the treatment of a wide range of lesions of the upper alimentary canal. The intestinal trefoil peptide therapy of this invention is particularly useful for treating epithelial lesions of the oral and esophageal mucosa, tongue, and gingival tissue.

Mammalian trefoil peptides were discovered in 1982. One of the mammalian trefoil peptides, human intestinal trefoil factor (ITF; TFF3), has been characterized extensively, and is described in U.S. Patent Nos. 6,063,755, and 6,221,840, hereby incorporated by reference. The other two known human 5 intestinal trefoil peptides are spasmolytic polypeptide (SP; TFF2) and pS2 (TFF1). Trefoil peptides, described extensively in the literature (e.g., Sands *et al.*, *Annu. Rev. Physiol.* 58: 253-273 (1996), hereby incorporated by reference), are expressed in the gastrointestinal tract and have a three-loop structure formed by intrachain disulfide bonds between conserved cysteine residues. These peptides 10 protect the intestinal tract from injury and can be used to treat intestinal tract disorders such as peptic ulcers and inflammatory bowel disease. Homologs of these human peptides have been found in a number of non-human animal species. All members of this protein family, both human and non-human, are referred to herein as trefoil peptides. Human ITF will be referred to most extensively in this 15 application; however, the activity of human ITF is common to each of the mammalian intestinal trefoil peptides.

We have discovered that epithelial lesions of the upper alimentary canal including the oral and esophageal mucosa, tongue, and gingival tissue can be treated by local administration of intestinal trefoil peptides. Thus, trefoil peptide 20 therapy, according to the methods of this invention, can be delivered in any pharmaceutical composition which is useful for delivering therapeutics to the upper alimentary canal.

Pharmaceutical Preparations

25 **Oral Sprays, Rinses, and Emulsions**

Spray systems are particularly useful for delivering therapeutics to the upper alimentary canal. Suitable spray delivery systems include both pressurized and non-pressurized (pump actuated) delivery devices. The intestinal trefoil peptide-containing solution, delivered as an oral spray, is preferably an aqueous 30 solution; however, organic and inorganic components, emulsifiers, excipients, and

agents that enhance the organoleptic properties (i.e., flavoring agents or odorants) may be included. Optionally, the solution may contain a preservative that prevents microbial growth (i.e., methyl paraben). Although water itself may make up the entire carrier, typical liquid spray formulations contain a co-solvent, for 5 example, propylene glycol, corn syrup, glycerin, sorbitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients. In general, therefore, the compositions of this invention preferably contain from about 1-95% v/v and, most preferably, about 5-50% v/v, of the co-solvent. When prepared as an spray, patients typically self-administer 1-5 times per day. The spray delivery 10 system is normally designed to deliver 50-100 μ l per actuation, and therapy may require 1-5 actuations per dose. The rheological properties of the spray formulation are optimized to allow shear and atomization for droplet formation. Additionally, the spray delivery device is designed to create a droplet size which promotes retention on mucosal surfaces of the upper alimentary canal and 15 minimize respiratory exposure.

Compositions suitable for oral sprays can also be formulated as an oral rinse or mouthwash. Administration of trefoil peptides using these formulations is typically done by swishing, gargling, or rinsing the oral cavity with the formulation. Optionally, these formulations can be swallowed, providing trefoil 20 peptide therapy to the esophagus, stomach, and/or intestines. This delivery method is particularly useful for treating patients suffering related disorders of the intestinal epithelium. For example, patients receiving antineoplastic chemotherapy, in addition to oral mucositis, frequently develop more distal 25 lesions of the gastrointestinal tract such as lesions of the gastric and intestinal epithelium. It is well known that intestinal trefoil peptides, particularly ITF, are stable at stomach pH. Thus, swallowing an intestinal trefoil peptide-containing solution designed primarily for treating oral mucositis may also benefit lesions of the lower alimentary canal (i.e., stomach and intestines).

In an alternative formulation, the intestinal trefoil peptides and/or other therapeutics can be encapsulated in bioerodible microspheres rather than being dissolved in the aqueous phase of the formulation. A wide variety of microencapsulation drug delivery systems have been developed and many share 5 similar polymeric compositions as used for bioerodable films (described below). Polymers commonly used in the formation of microspheres include, for example, poly- ϵ -caprolactone, poly(ϵ -caprolactone-Co-DL-lactic acid), poly(DL-lactic acid), poly(DL-lactic acid-Co-glycolic acid) and poly(ϵ -caprolactone-Co-glycolic acid) (see, for example, Pitt *et al.*, J. Pharm. Sci., 68:1534, 1979).

10 Microspheres can be made by procedures well known in the art including spray drying, coacervation, and emulsification (see for example Davis *et al.* Microsphere and Drug Therapy, Elsevier, 1984; Benoit *et al.* Biodegradable Microspheres: Advances in Production Technologies, Chapter 3, Ed. Benita, S, Dekker, New York, 1996; Microencapsulation and Related Drug Processes, Ed. 15 Deasy, Dekker, 1984, New York; U.S. Patent No. 6,365,187). Preferably, the microspheres are bioadhesive or are prepared in formulations containing a bioadhesive excipient.

Other technical features of the intestinal trefoil peptide-containing 20 solutions are easily modified to suit the specific pharmaceutical formulation and the clinical indication being treated. For example, the pH and osmolality of the formulation may be adjusted to confer trefoil peptide stability, while minimizing oral irritancy and sensitivity.

Ointments, Pastes, and Gels

25 Lesions of the oral and esophageal epithelium caused by trauma are amenable to trefoil peptide therapy delivered as an ointment, paste, or gel. The viscous nature of these types of preparations allows for direct application into the wound site. Optionally, the wound site can be covered with a dressing to retain the trefoil peptide-containing composition, protect the lesion from trauma, and/or 30 absorb exudate. As discussed further below, these preparations are particularly

useful to restore epithelial integrity following traumatic surgical procedures such as, for example, tooth extraction, tissue biopsy, or a tumor resection. Such viscous formulations may also have a local barrier effect thereby reducing irritation and pain.

5

Mucoadhesives

A mucoadhesive excipient can be added to any of the previously described pharmaceutical compositions. The mucoadhesive formulations coat the upper alimentary canal providing protection, inhibiting irritation, and accelerating 10 healing of inflamed or damaged tissue. Mucoadhesive formulations also promote prolonged contact of the intestinal trefoil peptide with the mucosal epithelium. Mucoadhesive formulations suitable for use in pharmaceutical preparations delivered by mouth are well known in the art (e.g., U.S. Patent No. 5,458,879). Particularly useful mucoadhesives are hydrogels composed of about 0.05-20% of 15 a water-soluble polymer such as, for example, poly(ethylene oxide), poly(ethylene glycol), poly(vinyl alcohol), poly(vinyl pyrrolidine), poly(acrylic acid), poly(hydroxy ethyl methacrylate), hydroxyethyl ethyl cellulose, hydroxy ethyl cellulose, chitosan, and mixtures thereof. These polymeric formulations can also contain a dispersant such as sodium carboxymethyl cellulose (0.5-5.0%).

20 Other preferred mucoadhesive excipients for liquid compositions are ones that allow the composition to be administered as a flowable liquid but will cause the composition to gel in the upper alimentary canal, thereby providing a bioadhesive effect which acts to hold the therapeutic agents at the lesion site for an extended period of time. The anionic polysaccharides pectin and gellan are 25 examples of materials which when formulated into a suitable composition will gel in the upper alimentary canal, owing to the presence of cations in the mucosal and salivary fluids. The liquid compositions containing pectin or gellan will typically consist of 0.01-20% w/v of the pectin or gellan in water or an aqueous buffer system.

30

Other useful compositions which promote mucoadhesion and prolonged therapeutic retention in the upper alimentary canal are colloidal dispersions containing 2-50% colloidal particles such as silica or titanium dioxide. Such formulations form as a flowable liquid with low viscosity suitable as a mouthwash or for generating a fine mist. However, the particles interact with glycoprotein, especially mucin, transforming the liquid into a viscous gel, providing effective mucoadhesion (e.g., U.S. Patent Nos. 5,993,846 and 6,319,513).

Bioerodable Film Delivery Devices

10 The most simple bioerodable devices contain the therapeutic agent(s) incorporated into a solid, usually lipid-containing, film or tablet. The device is formulated to remain solid at room temperature, but melt at body temperature, releasing the incorporated therapeutics. Suitable formulations of this type include, for example, cocoa butter.

15 Polymeric film devices provide several advantages for therapeutic delivery to the oral cavity. Unlike rinses, pastes, gels, and other flowable compositions, a film device can reside for prolonged periods of time (i.e., hours to days) in the oral cavity and provide sustained release throughout its residency. Typically, the film is partially or completely bioerodable and contains a mucoadhesive layer to 20 fasten the film to the oral mucosa. Film devices, in addition to its use for delivering therapeutics, can also provide protection against mechanical injury or microbial infection of a lesion site. This physical barrier function is particularly advantageous when treating conditions such as mucositis or aphthous stomatitis. Additionally, as discussed further below, a film device can be used to release 25 trefoil peptide therapy directly onto the underlying mucosa, into the lumen of the oral cavity, or a combination of both.

Film devices consist of at least two layers; a mucoadhesive layer suitable for attaching the film to the oral mucosa and a bulk layer which contains the active therapeutic(s). Many suitable mucoadhesives are known in the art and are 30 discussed above. Optionally, one or more therapeutics can also be provided in the

adhesive layer.

The bulk layer of the composite delivery device may be made of one or more bioerodable polymeric materials. Suitable polymers include, for example, starch, gelatin, polyethylene glycol, polypropylene glycol, polyethylene oxide, 5 copolymers of ethylene oxide and propylene oxide, copolymers of polyethylene glycol and polypropylene glycol, polytetramethylene glycol, polyether urethane, hydroxyethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, alginate, collagen, polylactide, poly(lactide-co-glycolide) (PLGA), calcium polycarbophil, polyethylmethacrylate, cellulose 10 acetate, propylene glycol, polyacrylic acid, crosslinked polyacrylic acid, hydroxyethyl methacrylate/methyl methacrylate copolymer, silicon/ethyl cellulose/polyethylene glycol, urethane polyacrylate, polystyrene, polysulfone, polycarbonate, polyorthoesters, polyanhydrides, poly(amino acids), partially and completely hydrolyzed alkylene-vinyl acetate copolymers, polyvinyl chloride, 15 polymers of polyvinyl acetate, polyvinyl alkyl ethers, styrene acrylonitrile copolymers, poly(ethylene terphthalate), polyalkylenes, poly(vinyl imidazole), polyesters and combinations of two or more of these polymers.

A particularly useful bulk layer polymer consists of PLGA and ethyl cellulose. PLGA is bioerodable and can be formulated to degrade over a wide 20 range of conditions and rates. Ethyl cellulose is a water-insoluble polymer that can act as a plasticizer for the PLGA when a film is formed, but will be eroded in a bodily fluid. Due to its water-insolubility, it also has an effect on the degree and rate of swelling of the resultant film.

An optional third layer which is impermeable to the trefoil peptide can also 25 be added to the wafer. Preferably, this barrier layer is also bioerodable. Suitable barrier layer polymers include ethyl cellulose, poly(acrylic acid), or other polyelectrolytes. In one configuration, the barrier layer is placed on the opposite side of the bulk layer relative to the adhesive layer, thereby directing the released therapeutic agent onto the contacted epithelium rather than being diluted in the 30 luminal fluid. This configuration is particularly useful for treating discrete

lesions (i.e., mucositis or aphthous stomatitis) of the tongue, sublingual tissue, or buccal mucosa. In an alternative configuration of the film device, the barrier layer is placed between the bulk layer and the adhesive layer. This configuration directs therapeutic release into the lumen of the oral cavity and is useful for 5 treating more diffuse lesions of the tongue, oral cavity, and esophagus. The configuration is also useful for delivering therapeutics which are cytotoxic when administered at high concentrations because it has the effect of shielding the underlying tissue from direct contact with the therapeutic-containing film.

10 Chewable Tablets, Lozenges, and Confectionaries

Preparing a trefoil peptide-containing composition as a chewable tablet, lozenge, or a confectionary such as chewing gum provides several advantages to traditional drug delivery vehicles. First, prolonged contact and sustained release at the target site (mouth and esophagus) is achieved. Second, such formulations 15 often results in higher patient compliance, especially when administering trefoil peptides to children.

Formulations for chewable tablets are well known and typically contain a base of sugar, starch, or lipid and a flavoring agent. An exemplary formulation for a chewable tablet is provided below.

20 *Chewable ITF Tablet Formulation (per tablet)*

Intestinal trefoil factor – 300 mg
Mannitol – 675 mg
Microcrystalline cellulose – 75mg
Corn starch – 30 mg
25 Calcium sterate – 22 mg
Flavoring Agent (i.e., sodium saccharin or peppermint oil)

30 The incorporation of therapeutics into chewing gum and other confectionary style formulations is known in the art (e.g., U.S. Patent No. 5,858,391).

Therapeutics AgentsTrefoil Peptides

In preferred embodiments, the trefoil peptide is a human trefoil peptide. More preferably, it is human intestinal trefoil factor (ITF), spasmolytic 5 polypeptide (SP), or pS2. Most preferably, the trefoil peptide is human ITF.

The trefoil peptides are present in the compositions of the invention at a concentration of between 0.1-1000 mg/ml, depending on the nature and condition of the lesion being treated, the anticipated frequency and duration of therapy, and the type of pharmaceutical composition used to deliver the trefoil peptide.

10 Typically, therapy is designed to deliver 0.1-500 mg of trefoil peptide per day to the patient.

Anti-Inflammatory Agents

Any suitable anti-inflammatory agent can be formulated in the 15 compositions of the invention, at concentrations known for these agents. Many of the most useful anti-inflammatory agents also have analgesic and/or antipyretic properties. Anti-inflammatory agents suitable for co-formulation with a trefoil peptide include, for example, acetaminophen, aspirin (acetylsalicylic acid), ibuprofen, phenylbutazone, indomethacin, sulindac, diclofenac, and naproxen.

20

Antimicrobial Agents

Any of the many known microbial agents can be used in the compositions of the invention at concentrations generally used for these agents. Antimicrobial agents include antibacterials, antifungals, antivirals, and other topical antiseptics.

25 Examples of antibacterial agents (antibiotics) include the penicillins (e.g., penicillin G, ampicillin, methicillin, oxacillin, and amoxicillin), the cephalosporins (e.g., cefadroxil, ceforanid, cefotaxime, and ceftriaxone), the tetracyclines (e.g., doxycycline, minocycline, and tetracycline), the aminoglycosides (e.g., amikacin, gentamycin, kanamycin, neomycin, 30 streptomycin, and tobramycin), the macrolides (e.g., azithromycin, clarithromycin,

and erythromycin), the fluoroquinolones (e.g., ciprofloxacin, lomefloxacin, and norfloxacin), and other antibiotics including chloramphenicol, clindamycin, cycloserine, isoniazid, rifampin, and vancomycin.

Antiviral agents are substances capable of destroying or suppressing the 5 replication of viruses. Examples of anti-viral agents include 1,-D-ribofuranosyl-1,2,4-triazole-3 carboxamide, 9->2-hydroxy-ethoxy methylguanine, adamantanamine, 5-iodo-2'-deoxyuridine, trifluorothymidine, interferon, adenine arabinoside, protease inhibitors, thymidine kinase inhibitors, sugar or glycoprotein synthesis inhibitors, structural protein synthesis inhibitors, 10 attachment and adsorption inhibitors, and nucleoside analogues such as acyclovir, penciclovir, valacyclovir, and ganciclovir.

Antifungal agents include both fungicidal and fungistatic agents such as, for example, amphotericin B, butylparaben, clindamycin, econazole, fluconazole, flucytosine, griseofulvin, nystatin, and ketoconazole.

15 Topical antiseptics include agents such as, for example, povidone-iodine and benzalkonium chloride.

Analgesics and Anesthetics

Any of the commonly used topical analgesics can be used in the 20 compositions of the invention. The analgesic is present in an amount such that there is provided to the oral lesion a topical concentration of between one-half and five percent concentration for lidocaine (5-50 mg/ml in 20-40 ml per dose of liquid). Examples of other useful anesthetics include procaine, lidocaine, tetracaine, dibucaine, benzocaine, p-buthylaminobenzoic acid 2-(diethylamino) 25 ethyl ester HCl, mepivacaine, piperocaine, and dyclonine.

Other analgesics include opioids such as, for example, morphine, codeine, hydrocodone, and oxycodone. Any of these analgesics may also be co-formulated with other compounds having analgesic or anti-inflammatory properties, such as acetaminophen, aspirin, and ibuprofen.

Steroids

Steroids are commonly used to treat lesions of the upper alimentary canal.

For example, oral aphthous stomatitis is typically treated using a paste preparation of triamcinolone (0.1%), hydrocortisone, fluticasone, or beclomethasone.

5

*Conditions of the Upper Alimentary Canal Treated Using Trefoil Peptides*Mucositis

Mucositis is a common condition of the oral cavity which is characterized by inflammation of the mucous membranes. The condition is frequently caused by antineoplastic therapy, including chemotherapy and local radiation therapy.

10 Symptoms of mucositis include ulcerations, redness, and swelling, and is associated with epithelial cell injury and death. Patients suffering from severe mucositis are susceptible to dehydration and malnutrition because mucositis pain limits dietary intake. In severe cases, mucositis can be so debilitating that patients 15 may require prolonged hospitalization, parenteral nutrition, and narcotic pain medication. Additionally, destruction of the mucosal epithelium increases a patient's susceptibility to local and systemic infection. Disruption of the barrier function permits entry of microorganisms and microbial products normally retained in the gut lumen. Thus, pharmaceutical preparations which reduce the 20 adverse effects associated with chemotherapy will improve the patient's quality of life, compliance with self-medication, and may permit administration of higher chemotherapeutic doses. Typically, mucositis is treated using a trefoil peptide-containing rinse or oral spray which the patient self-administers 1-5 times per day. The aqueous solution preferably contains a mucoadhesive and an anti- 25 inflammatory agent. Other therapeutics, such as an topical analgesic agent (e.g., lidocaine) may also be present. Alternatively, if the lesions are few in number and spatially localized, an intestinal trefoil peptide-containing film device an be placed directly over the lesions.

Tooth Extraction

Intestinal trefoil peptide-containing compositions of the invention are used to lessen complications and speed healing of the wound created by the extraction of a tooth. An oral rinse, paste, ointment, or gel, as described above, is applied to 5 the site of extraction immediately following the procedure and then 1-4 times per day, as needed, until epithelial regrowth is complete. Preferably, a topical analgesic is included in the formulation to relieve the temporary discomfort cause by the trauma of extraction. As a prophylactic measure, antibiotic agents may also be included in the formulation.

10

Gingivitis

Gingivitis is most commonly a chronic disease requiring ongoing treatment, in some cases for months or even years. The trefoil peptide-containing compositions of the invention can be employed to treat gingivitis, alone or in 15 conjunction with other treatments, particularly with an anti-microbial agent, and most commonly with an antibacterial agent. An oral intestinal trefoil peptide-containing rinse is swished in the patient's mouth at least once every 2-3 days, but as often as thrice daily, over a 3-4 week period, and the regimen is repeated as needed. Alternatively, the trefoil peptide is formulated into a gel or toothpaste. 20 In severe cases, a viscous gel or ointment having a high intestinal trefoil peptide concentration is applied directly to the wound via a plegget with a stick applicator.

Intestinal trefoil peptide-containing compositions can also be delivered in biodegradable drug delivery systems capable of formation of films applied below 25 the gum line (described in U.S. Patent Nos. 5,945,115 and 5,990,194. A biodegradable polymer, admixed with the intestinal trefoil peptide, is provided where the polymer can be injected in as a free-flowing solution below the gum line using a syringe. The polymer solution then, *in situ*, forms a solid biodegradable implant.

30

Aphthous Stomatitis

At the first indication of an outbreak of aphthous stomatitis (generally, the first twinge of pain), the patient swishes the mouth with an intestinal trefoil peptide-containing rinse, 1-4 times per day until the ulcer heals (generally 5-10 days). An intestinal trefoil peptide-containing gel can also be applied to the ulcer, in the same manner that steroid-containing gels are currently used. In addition, a gel can contain both an intestinal trefoil protein and a steroid known to be effective for aphthous stomatitis treatment. A direct application of more concentrated material can be directly applied to the wound via a pledge with a stick applicator. Alternatively, the lesion can be treated directly by applying a bioerodable film device containing both a trefoil peptide and a steroid (i.e., triamcinolone) directly to the lesion. Any formulation useful for treating aphthous stomatitis can also, optionally, contain a local anesthetic (i.e., lidocaine or benzocaine).

15

Behcet's Disease

Behcet's Disease is a rare, multi-system rheumatic disorder characterized by systemic vasculitis. One of the most frequent symptoms of Behcet's Disease is recurrent oral ulcerations which resemble aphthous lesions. Currently, treatment for Behcet's Disease is palliative, not curative. Thus, the intestinal trefoil peptides can be used to treat lesions of the upper alimentary canal in conjunction with currently available Behcet's Disease therapies including, for example, interferon alpha 2A and 2B, levamisole, cyclosporine, cyclophosphamide, and colchicine.

25

Oral Biopsy and Oral Surgery

In cases in which an oral neoplasm is suspected or known to be malignant, a biopsy or a curative resection is performed using a needle or a scalpel, resulting in an open wound. The surgical area, susceptible to infection and inflammation, is treated by rinsing with a trefoil peptide-containing solution 1-4 times per day.

Preferably, an analgesic, an anti-inflammatory, and an antibiotic are included in the formulation. Alternatively, a more concentrated gel, paste, or ointment may be directly applied to the lesion site. For post-operative treatment following resection of a malignancy, a topically active chemotherapeutic can be including in 5 the trefoil peptide-containing composition.

Thermal and Chemical Burns

Trauma to the upper alimentary canal is frequently caused by exposure to excessive heat or noxious chemicals. Thermal burns to the upper alimentary canal 10 are frequently mild in nature (i.e., first or second degree burns), resulting from the ingestion of overheated food or drink. More severe thermal burns of the oral mucosa and upper esophagus can be caused by inhalation of super heated air and are frequently observed in firefighters or victims of house or forest fires.

Chemical exposure can also damage the mucosa of the upper alimentary canal. Mild mucosal irritations and burns are often caused by ingestion of acidic 15 food (i.e., fruits). More severe chemical burns are usually associated with accidental industrial or occupational exposures.

The intestinal trefoil peptide-containing pharmaceutical formulations described herein are useful for treating thermal and chemical burns of the upper 20 alimentary canal. Preferably, viscous liquid or gel formulation containing a mucoadhesive is used to prolong mucosal exposure to the trefoil peptide. Alternatively, a sustained release formulation, such as a bioerodable film, is used. Topical analgesics and antimicrobial agents are the most preferred secondary therapeutics to be co-administered.

25

Production of Intestinal Trefoil Peptides

Intestinal trefoil peptides can be produced by any method known in the art for expression of recombinant proteins. Nucleic acids that encode trefoil peptides (e.g., human intestinal trefoil factor (Figure 4 and 7), human pS2 (Figure 5 and 8), 30 and human spasmolytic polypeptide (Figure 6 and 9) or fragments thereof may be

introduced into various cell types or cell-free systems for expression thereby allowing large-scale production, purification, and patient therapy.

Eukaryotic and prokaryotic trefoil peptide expression systems may be generated in which an intestinal trefoil peptide gene sequence is introduced into a 5 plasmid or other vector, which is then used to transform living cells. Constructs in which the intestinal trefoil peptide cDNA contains the entire open reading frame inserted in the correct orientation into an expression plasmid may be used for protein expression. Prokaryotic and eukaryotic expression systems allow for the expression and recovery of intestinal trefoil peptide fusion proteins in which 10 the trefoil peptide is covalently linked to a tag molecule which facilitates identification and/or purification. An enzymatic or chemical cleavage site can be engineered between the trefoil peptide and the tag molecule so that the tag can be removed following purification.

Typical expression vectors contain promoters that direct the synthesis of 15 large amounts of mRNA corresponding to the inserted intestinal trefoil peptide nucleic acid in the plasmid-bearing cells. They may also include a eukaryotic or prokaryotic origin of replication sequence allowing for their autonomous replication within the host organism, sequences that encode genetic traits that allow vector-containing cells to be selected for in the presence of otherwise toxic 20 drugs, and sequences that increase the efficiency with which the synthesized mRNA is translated. Stable long-term vectors may be maintained as freely replicating entities by using regulatory elements of, for example, viruses (e.g., the OriP sequences from the Epstein Barr Virus genome). Cell lines may also be produced that have integrated the vector into the genomic DNA, and in this 25 manner the gene product is produced on a continuous basis.

Expression of foreign sequences in bacteria, such as *Escherichia coli*, requires the insertion of an intestinal trefoil peptide nucleic acid sequence into a 30 bacterial expression vector. Such plasmid vectors contain several elements required for the propagation of the plasmid in bacteria, and for expression of the DNA inserted into the plasmid. Propagation of only plasmid-bearing bacteria is

achieved by introducing, into the plasmid, selectable marker-encoding sequences that allow plasmid-bearing bacteria to grow in the presence of otherwise toxic drugs. The plasmid also contains a transcriptional promoter capable of producing large amounts of mRNA from the cloned gene. Such promoters may be (but are not necessarily) inducible promoters that initiate transcription upon induction. The plasmid also preferably contains a polylinker to simplify insertion of the gene in the correct orientation within the vector. Mammalian cells can also be used to express a trefoil peptide. Stable or transient cell line clones can be made using intestinal trefoil peptide expression vectors to produce the trefoil peptides in a soluble (truncated and tagged) form. Appropriate cell lines include, for example, 10 COS, HEK293T, CHO, or NIH cell lines.

Once the appropriate expression vectors are constructed, they are introduced into an appropriate host cell by transformation techniques, such as, but not limited to, calcium phosphate transfection, DEAE-dextran transfection, 15 electroporation, microinjection, protoplast fusion, or liposome-mediated transfection. The host cells that are transfected with the vectors of this invention may include (but are not limited to) *E. coli* or other bacteria, yeast, fungi, insect cells (using, for example, baculoviral vectors for expression in SF9 insect cells), or cells derived from mice, humans, or other animals. *In vitro* expression of 20 trefoil peptides, fusions, or polypeptide fragments encoded by cloned DNA may also be used. Those skilled in the art of molecular biology will understand that a wide variety of expression systems and purification systems may be used to produce recombinant trefoil peptides and fragments thereof. Some of these systems are described, for example, in Ausubel *et al.* (Current Protocols in 25 Molecular Biology, John Wiley & Sons, New York, NY 2000, hereby incorporated by reference).

Transgenic plants, plant cells and algae are also particularly useful for generating recombinant intestinal trefoil peptides for use in the methods and compositions of the invention. For example, transgenic tobacco plants or cultured 30 transgenic tobacco plant cells expressing an intestinal trefoil peptide can be

created using techniques known in the art (see, for example, U.S. Patent Nos. 5,202,422 and 6,140,075). Transgenic algae expression systems can also be used to produce recombinant intestinal trefoil peptides (see, for example, Chen et al., Curr. Genet. 39:365-370, 2001).

5 Once a recombinant protein is expressed, it can be isolated from cell lysates using protein purification techniques such as affinity chromatography. Once isolated, the recombinant protein can, if desired, be purified further by e.g., high performance liquid chromatography (HPLC; e.g., see Fisher, Laboratory Techniques In Biochemistry And Molecular Biology, Work and Burdon, Eds., 10 Elsevier, 1980).

Polypeptides of the invention, particularly short intestinal trefoil peptide fragments can also be produced by chemical synthesis using, for example, Merrifield solid phase synthesis, solution phase synthesis, or a combination of both (see, for example, the methods described in Solid Phase Peptide Synthesis, 15 2nd ed., 1984, The Pierce Chemical Co., Rockford, IL). Optionally, peptide fragments are then be condensed by standard peptide assembly chemistry.

Example 1: Mucositis Treatment for Patients Receiving Antineoplastic Therapy

20 Trefoil peptide therapy is initiated prior to antineoplastic therapy (i.e., chemotherapy or radiation therapy), as a prophylactic to delay or prevent the onset of mucositis. Preferably, the patient begins intestinal trefoil peptide therapy three days prior to the first dose of antineoplastic therapy. During the prophylactic stage, the patient rinses the oral cavity with an intestinal trefoil peptide-containing 25 solution. Alternatively, for convenience, the trefoil peptide is provided as a concentrated oral spray. Preferably, the patient swallows the solution, providing protection for the epithelial cells of the esophagus and lower gastrointestinal tract. Rinsing with and swallowing the intestinal trefoil peptide-containing solution continues at least twice daily until oral or esophageal mucositis is detected.

In patients with existing mucositis, epithelial healing is promoted using intestinal trefoil peptide therapy as described above. Palliative therapy is provided using benzocaine (a local anesthetic), and nystatin (an antifungal). The intestinal trefoil peptide can be co-formulated with the benzocaine and nystatin.

5 For example, the patient swishes an oral rinse solution (mouthwash), containing all therapeutic agents, 1-5 times each day. Alternatively, the trefoil peptide can be provided in a concentrated oral spray, with or without benzocaine and the nystatin is administered in an oral rinse.

The oral rinse solutions can either be swallowed or spit out. If swallowed, 10 an antacid may also be included in the formulation. Other useful therapeutics which provide palliative therapy include anti-inflammatories (e.g., ibuprofen) and other anti-microbial agents. Exemplary oral rinses useful for treating chemotherapy-induced mucositis are provided below, but are not intended to be limiting. A skilled physician or pharmacist will immediately recognize 15 appropriate substitutions, additions, and deletions that can be made to these formulations.

Rinse#1: Mix equal parts of:

- (i) diphenhydramine elixir (Benadryl®)
- (ii) kaolin-pectin suspension (Kaopectate®)
- 20 (iii) viscous lidocaine HCl (2%)
- (iv) nystatin (oral suspension; 100,000 iu/ml)
- (v) ITF (2.5 mg/ml)

preferably swallowed after swishing

25 Rinse#2: Mix equal parts of:

- (i) diphenhydramine elixir (Benadryl®)
- (ii) Maalox® (MgOH & AlOH; 40 mg/ml)
- (iii) viscous lidocaine HCl (2%)
- (iv) ITF (2.5 mg/ml)

30 preferably swallowed after swishing

Other Embodiments

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

What is claimed is:

CLAIMS

1. A method for treating a lesion of the upper alimentary canal of a mammal comprising administering to said patient a therapeutically effective amount of an intestinal trefoil peptide.

5

2. The method of claim 1, wherein said intestinal trefoil peptide is spasmolytic polypeptide, pS2, or intestinal trefoil factor.

10 3. The method of claim 2, wherein said intestinal trefoil peptide is intestinal trefoil factor.

4. The method of claim 1, wherein said mammal is a human.

15 5. The method of claim 1, wherein said lesion is mucositis.

6. The method of claim 1, wherein said lesion is aphthous stomatitis.

7. The method of claim 1, wherein said lesion is caused by antineoplastic therapy.

20

8. The method of claim 7, wherein said antineoplastic therapy is radiation therapy.

25

9. The method of claim 7, wherein said antineoplastic therapy is chemotherapy.

10. The method of claim 1, wherein said lesion is the result of gingivitis.

30

11. The method of claim 1, wherein said lesion is the result of tooth extraction.

12. The method of claim 1, wherein said lesion is the result of a biopsy procedure or surgical intervention.

5 13. The method of claim 1, wherein said lesion is the result of tumor resection.

14. The method of claim 1, wherein said lesion is caused by thermal or chemical burn.

10

15. The method of claim 1, wherein said lesion is caused by Behcet's Disease.

15 16. The method of claim 1, wherein said lesion is caused by a bacterial, viral, or fungal infection.

17. The method of claim 1, further comprising administering to said mammal a second therapeutic.

20 18. The method of claim 17, wherein said second therapeutic agent is an anti-inflammatory agent.

19. The method of claim 17, wherein said second therapeutic agent is an antibacterial agent.

25

20. The method of claim 19, wherein said antibacterial agent is a penicillin, a cephalosporin, a tetracycline, or an aminoglycoside.

30 21. The method of claim 19, wherein said antibacterial agent is povidone-iodine.

22. The method of claim 17, wherein said second therapeutic agent is an anti-fungal agent.

5 23. The method of claim 22, wherein said anti-fungal agent is nystatin or Amphotericin B.

24. The method of claim 17, wherein said second therapeutic agent is an anti-viral agent.

10

25. The method of claim 24, wherein said anti-viral agent is acyclovir.

26. The method of claim 17, wherein said second therapeutic agent is an analgesic.

15

27. The method of claim 26, wherein said analgesic is lidocaine or benzocaine.

28. The method of claim 17, wherein said second therapeutic agent is a
20 steroid.

29. The method of claim 28, wherein said steroid is triamcinolone or hydrocortisone.

25 30. The method of claim 17, wherein said trefoil peptide and said second therapeutic are administered in the same formulation.

31. The method of claim 17, wherein said trefoil peptide and said second therapeutic are administered in different formulations.

30

32. The method of claim 31, wherein said trefoil peptide and said second therapeutic are administered within 24 hours of each other.

33. The method of claim 32, wherein said trefoil peptide and said second therapeutic are administered within one hour of each other.
5

34. A composition suitable for therapeutic delivery to the upper alimentary canal of a mammal, said composition comprising an intestinal trefoil peptide.

10 35. The composition of claim 34, wherein said intestinal trefoil peptide is spasmolytic polypeptide, pS2, or intestinal trefoil factor.

36. The composition of claim 35, wherein said intestinal trefoil peptide is intestinal trefoil factor.
15

37. The composition of claim 34, wherein said composition is an oral spray.

20 38. The composition of claim 34, wherein said composition is an oral rinse.

39. The composition of claim 34, wherein said composition is a bioerodible film.

25 40. The composition of claim 34, wherein said composition comprises microspheres.

41. The composition of claim 37, 38, 39, or 40, wherein said composition further comprises a mucoadhesive agent.
30

42. The composition of claim 34, wherein said composition is a chewing gum, lozenge, or chewable tablet.

43. The composition of claim 34, wherein said composition further
5 comprises a second therapeutic agent.

44. The composition of claim 43, wherein said second therapeutic agent is an anti-inflammatory agent.

10 45. The composition of claim 43, wherein said second therapeutic agent is an antibacterial agent.

46. The composition of claim 45, wherein said antibacterial agent is a penicillin, a cephalosporin, a tetracycline, or an aminoglycoside.

15 47. The composition of claim 45, wherein said antibacterial agent is povidone-iodine.

20 48. The composition of claim 43, wherein said second therapeutic agent is an anti-fungal agent.

49. The composition of claim 48, wherein said anti-fungal agent is nystatin or Amphotericin B.

25 50. The composition of claim 43, wherein said second therapeutic agent is an anti-viral agent.

51. The composition of claim 50, wherein said anti-viral agent is acyclovir.

52. The composition of claim 43, wherein said second therapeutic agent is an analgesic.

53. The composition of claim 52, wherein said analgesic is lidocaine or
5 benzocaine.

54. The composition of claim 43, wherein said second therapeutic agent is a steroid.

10 55. The composition of claim 54, wherein said steroid is triamcinolone or hydrocortisone.

FIGURE 1

1 MLGLVLALLS SSSAEEYVGL SANQCAVPAK DRVDCGYPHV
41 TPKECNNRGC CFDSRIPGVP WCFKPLQEAE CTF

FIGURE 2

1 MATMENKVIC ALVLVSMAL GTLAEAQTET CTVAPRERQN
41 CGFPGVTPSQ CANKGCCFDD TVRGVPWCFY PNTIDVPPEE
81 ECEF

FIGURE 3

1 EKPSPCQCSR LSPHNRTNCG FPGITSDQCF DNGCCFDSSV
41 TGVPWCFHPL PKQESDQCVM EVSDRRNCGY PGISPEECAS
81 RKCCFSNFIF EVPWCFFPNS VEDCHY

FIGURE 4

1 atgctggggc tggcctggc cttgctgtcc tccagctctg ctgaggagta cgtgggcctg
61 tctgcaaacc agtgtgcccgt gccagccaag gacagggtgg actgcggcta ccccccattgtc
121 acccccaagg agtgcaccaa ccggggctgc tgcttgact ccaggatccc tggagtgcct
181 tggtgtttca agccctgca ggaagcagaa tgcaccccttca ga

FIGURE 5

1 atggccacca tggagaacaa ggtgatctgc gccctggtcc tggtgtccat gctggccctc
61 ggcacccctgg ccgaggccca gacagagacg tgtacagtgg ccccccgtga aagacagaat
121 tgtggtttc ctgggtgtcac gccctcccaag tgtgcaaata agggctgctg tttagacgac
181 accgttcgtg gggtcccttg gtgcttctat cctaataccca tcgacgtccc tccagaagag
241 gagtgtgaat tttag

FIGURE 6

1 atgggacggc gagacgccc a gtcctggc a ggcgtccctg tccctgggct atgtgccctg
61 gcggggagtg agaaaccctc cccctgccag tgctccaggc tgagccccca taacaggacg
121 aactgcggct tccctggaat caccagtac cagtgtttt acaatggatg ctgtttcgac
181 tccagtgtca ctggggtccc ctgggtttc caccctcc caaaggcaaga gtcggatcag
241 tgcgtcatgg aggtctcaga ccgaagaaac tgtggctacc cgggcatcag ccccgaggaa
301 tgcgcctctc ggaagtgcgt cttctccaaac ttcatctttg aagtgccctg gtgcttcttc
361 ccgaagtctg tggaagactg ccattactaa

FIGURE 7

(page 1 of 2)

1 atgctggggc tggcctggc cttgctgtcc tccagctctg ctgaggagta cgtgggcctg
61 tgtgagtact gccctgactg ccccggtggc agggtggcg tgaagggaag ggatccagga
121 taagggggga ttctgcattc attaataat gcccacctgt cacatataca cttttcctg
181 cgctagccct ttgaagtggg tctttattgt ccccatttca cagacaagga aaccgaggct
241 cagagaaagt taacaactta tccaaggcag ccctgcccag tctgtgttga aatcagggtt
301 tgagcctgag cccatcccct atgacccat agccatctt gctggagatt tctaaattac
361 aatataggc tttatgcatt gttccacatt tacaaagaaa aaggaaagat gcaggagaaa
421 aaccctgact tcagaacact gtcaataccg gcaggcacaa ggttcatttta gccattgcat
481 agcaaccctg ccatgggtg tggctgtcc attaacccaa gtttgaagga atgagggcat
541 ggcttttatac tgggtgtctt ctgagcaggg tcaaaggcag tggttcccg acttgcagcc
601 cattagaatc acctggagag cttaaaaaat cctaattgtt ggggcacacc agttacatca
661 gggcatctcc aggcaagatc caggcctcaag ctgtttgtt ttgagatagc cttgctttgt
721 cactcactgc tggagtgcag tggcacaatc tcagctcaact gcaacctccg ctcctgggt
781 tcaagcaatt cttgtgcctc ggcttcaagt agctggattt acaggcatgc accaccatgc
841 ccagctaatt ttttggattt tttagtagaga tggagtttcg ctatgttgc caagctggc
901 tcaaactcct ggcctcaagt gatcctccctg ctttggccctc ccaaagtgtt ggaattacag
961 gtgttaagcca ccatggccag ccaacgtcag tcattttaa agctctgcag ctgattccag
1021 tgtgagcgaat gtttggatgc caggaggata agcaattacg gactgggagc aagagaaggg
1081 aatgttaagac actgcacgtg attgccattt tcctaaggaa atactcagtt cgtaatgaa
1141 acgcagtgaa cttctgctgc acatacagac atagaggctt gcctgaaaaca tgaaaatatt
1201 ggggactgaa ggtatcccg ggagggtggg acatgctcaa caattcagga agggagatg
1261 cagaaaaaaag tgaaaagcag gcagcatgcg ttgcaatgtt ctctatggcg tgcctctc
1321 ctgtcacggc tttcatttaa aacaaaagggg caaggtttt ttgtcaaac aatgaagggt
1381 aactttgtt ctgggttcaa gggaccccg attccccagg ggttctgtcc agctggagg
1441 tacccagggtc cgtatgtgac ttcccggagaa ggtgataaga gctgtccaa gagaaagaca
1501 cttaggcaaa tggccagagt ccccgagctg agcatttaac agactgcctc tctttaata
1561 ttcacaggga aagtgcattt tcctaagggc gaggtttca gcaagtgggtt aactcggcgg
1621 ggtggggccg agcgggagga tgcaaaacttgc caaagtgaag caaacacact caccgcagcc
1681 cagcaaggcc tctggcagct gacagggtt tgcctgggac agctgcacac cagtgtggcg
1741 tgccagccaa ggacagggtg gactgcggct accccatgt cacccttcaag gagtgcacaca
1801 accggggctg ctgctttgac tccaggatcc ctggagtgcc ttgggtttc aagccctgc
1861 aggaagcagg taaggccccaa gtggcatctg ggtctggcc cagccccata aggcagggggg
1921 tctcaggccc tccctgtccct ttctgggctg gagatggagg cacaaggacc ccaggaagcc
1981 acacacacac acctgttcca aggccctcaga gcagaggctt cacacttagg gcagccatgg
2041 ccaggggctg tcctcttctg tcccctttat gtaaaacata aagcaattt tttcaaaaag
2101 gtgttcaaaa tgatggcatc gcatagaggg aactgattt gtaactattt ttgagagaag
2161 tggaaacgca tagtgttgcg aagccggcc gactttggg ctgttttgc aaatcgccc
2221 cccagagtct tgcattttgtt ggcattccctt acacagacgg caggcggcc cagccctaga
2281 cgtcaggcct cgggtccaca ccccacctcc cccactctgc ccccccacaag ggtcatctcc
2341 tctccctctc tctggcgtgg tggagggcag gtgcaggcc accaccctgg gggttccctc
2401 cccaggggccg gagagcctgc gtgcgtgcg ggttaacagat ggcctgcac acgggtttgc
2461 caccctggct ccaccaggct tagctggccc acatgtggg tggggcgatt ggctataagc
2521 catctggccat gtccaaagtgc cagctcagcc cccacgaagg ccgcacctgc gtgaggtacc
2581 ttcctggaaac cagcatccag agggccctt cttggccctt gtccttaggtt gaaatgcggg
2641 aggctgagtc ctgctggccc cggctccctg atcaatgtt ggcctgtcc caggccctcc

FIGURE 7

(page 2 of 2)

2701 cttcacccctc cccagcaagt ccagggtagg ggtgggggtg ggggtccaga gaaggccagg
2761 agagagaggg gtctggctac tgtccactgc cggctctgtt ccttcagctc cactggaact
2821 acactctcct ctgagtgcca gccatggccc tgccaaggcc catctcgctt gttatctgcc
2881 tgatccctgg gtcccactat cttgcttagc aacccgaggt ggaaatcttg gctattcccc
2941 catgtggtgg ggactcaaca ctccccggtg actctggga ggagggcagca ctaggtgctg
3001 gccttgagc ctgcccgtac cttgggaagc tggcagcgt gggtggagag agactgctca
3061 cacaaggcctt tgctctgttt gcagaatgca ccttctgagg caccctccagc tgccccggc
3121 cgggggatgc gaggctcgga gcaccctgc ccggctgtga ttgctgcag gcactgttca
3181 tctcagcttt tctgtccctt tgctccggc aagcgcttct gctgaaagtt cataatctgga
3241 gcctgatgtc ttaacgaata aaggccccat gctccacccg

FIGURE 8

(page 1 of 2)

1 ccctgggtg cagctgagct agacatggga cggcgagacg cccagctcct ggcagcgctc
61 ctcgtcctgg ggctatgtgc cctggcgggg agttagaaac cctgttaagtg aaggagaggg
121 tctttttatg tgctttctt atttctctt aagaaaaaaa aaaagcacaa ccataaaatta
181 acttgagagg gggaatggct ataaaggcat ctggcaatgt gtgtgttca catgggattt
241 gccactgctc aggagggtgg ctccaagaag ggcctccctc cttagggaaag gctgagtgac
301 ggcaggtgtc agcggggcccc gtgtcgggcc aggaggcat tcccaccaag ggtccttgga
361 gtcccagagc actcacctct cgcctggatc ttggccttgg gtccatctgt tcaccctcct
421 ctaggagggt ttttttttgg tttttttccg agacaggatc tggctttgcc gcccaggcag
481 gagtgcagtg gtgtgatctt ggctcaactgc aacctctgcc tcccaggctc aagtgatcct
541 cccacccatcg ccgcctgagt agctgaaacc acagttgtgg accatcatgc cccggcaatt
601 ttttttttgg tattgtttgt agagatgggg tttcgacatg ttgcccagga tggctttgaa
661 ctcctgagct caagaatct gcccgcctcg gcttcctaaa gtgctgggat tataaggtatg
721 agccaccatg cctggctttt tttttttttt ccttttaaac taatataaca atttcagcaa
781 agccctatcg gcttctcagg agggaaaccgc attgcttaaa tatgggcaag ataagacttt
841 gtgtttctct atgtggcaac aagacagtagt aggcacatcccc tagaacctct gagagaagga
901 gcagtgtgtt ctgggttacc aggggtgggc cgactgaggg tctttccaca gccccctgcc
961 agtgctccag gctgagcccc cataacagga cgaactgcgg ctccctgga atcaccagtg
1021 accagtgttt tgacaatggg tgctgtttcg actccagtgt cactgggtc ccctgggtt
1081 tccacccccc cccaaagcaa ggtaatcttc cagggatct tcctgggcca gcagctggca
1141 acccaggacc cagcttcaca ggcggagccc agagcagggg cccgaggagg cccagttct
1201 agtcttagggt tagcctgggt gggtttagtct cgagctagcc cccggttgggt agtctggggc
1261 tagcccaggt tggttagtct agagctagcc caggttgggt agtctggggc tagcccaggt
1321 tggttagtct gggctagcc caggttgggt agtctagggc tagttaggc tagtttagtct
1381 aaggctagcc caggttgggt agtttggagc tagcgcaggt tggttagtct gggctagta
1441 gcccaggttg gtaggcctgg agctagccca gggttggtag tctagggcta gcgtaggctg
1501 gttagtcctgg ggctagccca gggttggtag tctggagcta gcccaggttg gttagtcctgg
1561 ggctagtagc ccaggttgggt tagtctgggg ctagcccagg ttggtagtgc tagggctagt
1621 gtaggctagt tagtcttaggg ctagcccagg tttagtttgc tgtagctagc acaggtttagt
1681 tagtctgggg cttagtagcct aggttgggttgc gtctggagct agcccaagtt ggtagtctta
1741 gggctagcat aggctggta gtctgggtc agtagcctag gtttggtagt ctggagctag
1801 cccaggttgg tttagtcttagg gctagcgtag gctggtagt ctaggctag cccaggttgg
1861 ttaatcggag ctagcccagg ttggtagtgc tgtagctagc ccaggttgggt tagtctgagg
1921 cttagtagccc aggttggta gtctgggtc agcccaaggtt tgtagtctg gagctagccc
1981 aggttggta gtctggagct agcccaagggtt ggtagtctg ggactagctt ggactgctag
2041 tctagaggtt gcttagagga ctgcttagtct agaggttagc tagggctagc ccaggttgg
2101 tagtctgggg ctagcccattt ttggtagtgc tttagactagc ctggactgtct agtctagagg
2161 tagcccaggat tggttagtct ggtactagcc tggactgtta gtcttagaggtt agcccaagggtt
2221 ggtaggttgc tttagtctgg gactgtctg gactgttagt cttagaggtt gggccatcc
2281 tttagtctggg actagcctgg actgttagtgc tagaggttagc ccagattgggt tagtctgg
2341 cttagtctgaa ctgcttagtct agaggttagcc caggttgggtt agcctggggc cagctggac
2401 tgtagtctca gaggttaccc aggtcagccca acagttagat gaaaatttcc cacctaccct
2461 gtttctacac tgtagttct ttcaacagac atgtgtgtgtt ggagccatca gtttacttt
2521 aggttggaaa aaaatataataatataatgt aggtctccctc tagtttttga agtgtgactt
2581 ctgaagaagc ttccatgggg aaatgaaggtt attaatagg acagcagtaa cataaggcct
2641 gacagccctc aaatgttagg gaaggaagtg aagccttctta gggttcttgg ggagttagt

FIGURE 8

(page 2 of 2)

2701 ttatgttagt gcacgggatc aggacccaag ttgttaacgcc gacgagtgct caaaggaagg
2761 ttgtgtgtgt gtctgcacc tgggtgcgtg gaaccaggca cgtccctctgg agaaggagga
2821 ttcatccccca agattgtgc tgggaggctt gctggggccc gcagggaaac caggcagatg
2881 gtggattgtt cacgagcgcc cactgaatgg cagtgtcttt gggaaatcaat accatgtcca
2941 aacgccttcc atcttaccaa ggtgcccaca aacctttct catcttgcc cgggggacca
3001 ccccatttac tgagaacact gatgtcccgag agccaaaatg atttcccaa ggccggggac
3061 tccagagctt ctgactgtga ccacccaca tggcccccac ctgcggag gacaggccag
3121 ccaagcgctcg ctggggccga cactccaca gtccccgggg gaggcggtcc caggggcccga
3181 cacttccaca gtccccgggg gaggccgtcc cgggggatgc tgccccaggc agcacctcat
3241 gatccacgga ggctgcaaat cagcgtctgt ctcaagaggag gaaggggtgg agctttccag
3301 ggcacagcag gcctgactgg gtctcggtgc tggctgtc ccatggcaga gtcggatcag
3361 tgcgtcatgg aggtctcaga ccgaagaaac tggcttacc cgggcattcag ccccgaggaa
3421 tgcgcctctc ggaagtgtcg cttctccaaat ttcatctttg aagtgcctcg gtgcctctc
3481 ccgaagtctg tggaaaggtaa cgtcgctgtg ggactctctg tctgggtcccc ggacaccatg
3541 attcctcctc cgtccgtaga ggtgggtgc agggagggga gtcgcctcgc agcctcagtg
3601 ccatcgaggc caggccccct gcctcctatg ggattctgaa ggcaattcca gaatgttctt
3661 ggcaaagaca gcgtctttc aataagtta tagcctccag cattgccact gcgtcatctg
3721 tggatggctct agaaacagcg gctcatccct gttgcctccc caggtgtgc aacgttcaga
3781 ggcgttgcct gtttattgc aagcccatct gcatttggag gctactgagt gtcttgact
3841 gtgcgtggta ccagagaggg cccaaactcaa gcagacctgg ccccttcgc cgtggcttcc
3901 ccgttctccc ccacatgacc cccaaatgaca aacccatcc acaacgtcct gtcggggca
3961 gtcccgggag ggtcccgccg gcagaggtga acgggtccac ttctccacc cgcttagtga
4021 tagtgttgc ctgactcgga gtgtggcgag gtaaaaaaaaa accaagcaga tccaggaaaa
4081 tggggaaaga gctactggcc cttgaaggat gcctttctt ttccctttgt taggatata
4141 aagcactcca aagagcgaaa tatttcatgt tcaggatttt ccgagtgtt tttttatgt
4201 gacctaagg tccacctaga aaatgttccac ttgtctgggg agaatgcgcc ccacagagga
4261 aactctggcc tgggtggga agatttggc ccttacacc ccctccccgg gaaaggagct
4321 cttcttcag taggaagctc ctggcaaaag tgatgcacgc ccaccccgcc ttgcagccct
4381 aggcactccc attctgggg ttcccttacc aaccatctt cattttaact tctagactgc
4441 cattactaag agaggctggt tccagaggat gcatctggct caccgggtgt tccgaaacca
4501 aagaagaaac ttgccttat cagttcata cttcatgaaa tcctgggttt tcttaaccat
4561 ctttcctca tttcaatgg tttaacatata aatttctta aataaaaccc ttaaaaatctg
4621 ct

FIGURE 9

(page 1 of 2)

1 atccctgact cggggtegcc tttggagcag agaggaggca atggccacca tggagaacaa
61 ggtgatctgc gccttggtcc tgggtccat gctggccctc ggcaccctgg ccgaggccca
121 gacaggttaag gcgtgtttct tcctgtctg tggggccaca gccagctctg gcagcctcg
181 ccaggagcca ctgttttaca tacatatttt tgagcacctg ttttgtgcca ggtgtgttc
241 taggccccta aaagtataatc caatttacag gatcggcaaa agcaggtgga gagtaactca
301 ggggtggcagg gccccccggag accttcgaga agtgcacga ggagggggct gccttcagtc
361 ggggctgttt tcctgtgtta ggaagactat acaatccctcc caagtgtcat gtttcaaaga
421 ggaagtgttg gcgtgggggtc tcagaatagt gctttgact gttcatgcca acatctcccc
481 caggggcaga ccctcccaag gcccattccag ataggcccaa atgcccgtcc cagtgtatggc
541 cacctgggag accctctccc acaggcccgaa atgcccgtcc cagtgggtgc caactgggag
601 accctctccc acaggttccct gggctccctt gggatccatg ctctgggagt caaagccacc
661 tctctcatga gtgcgtggct ggcaaccat attccctggt gttgtcaagt ggatcggttg
721 ccctgggtcc ttcttagggag tggaggagga ggcatttctt gtttcctgg gaaatgtttt
781 catctcaact cctttacctg cagaatggat caacggctcg cccttagggct gtcaggaaat
841 gctgtgtggc agcatctgcg acttgcaccc ttgcagctgt ggggagctga ataacttatt
901 tgccgttatt aggtacagtt tcaaggtggg ggcaggagaa agggcttct acgtttccaa
961 agcaagggtt tccagagagg cctgaagagg gagegccccag tgggtctgtc cgtgccccca
1021 ctgcccctcca gccaccttctt gatctctgt gtggggtaacc gggcctgagg ggtgggcttg
1081 ggcagcgtag aagagcagcc agcattggc tgcaatgggaa agaccccca gcccattggca
1141 gggagcgggg gagctttgga accccggaga ggaatgtggcc tcgggtgtaca gaacgaactg
1201 ggtgggtccc cgtgtggcc accccccaggc ccattctgcct ggcgccttgc ccccccaccca
1261 gccccccagct ctgccccctg tgctgtggta tcacagaggc cgtggcaaac tccccctcccc
1321 accccacaca ccctctggct caaggctctg agcgttccctt cgggtcaactc aggtccatga
1381 ttctgttaca actgaaatct agaaaattgt gattacagtt tagtgcattc gtgtgtggaa
1441 accatttcca tttatttcca tcatgcaca aagacaaaagc ggggtggcaaa gacagagtc
1501 gcccggaggca gagcaccggg gctggaaatc ttccctccctg aggagggaaac ccccccggacc
1561 cccaggatga tgatccccc tcaccacggg gcctcttttgc accccccacag tgcgggggg
1621 gtggggcgatg atcacccctca cgtgcgtatc gatccagacc ccaggaggc aaggttccca
1681 tggaaagctgc tggggcagcg gagctgaaca cggatccctc ccagcaagcc aggaacactt
1741 tctccaaaga catctcgagg cagtcctgtc tagcaaaagca gacaagagaa cagccctct
1801 cggccctcccc tggggcggcc tcacctgagc cagttgtggcc agactgagtt cctccctcc
1861 tatgccccaa ggcaggagca gggaccggag ggtgtctgg gctccctttt cacccttgc
1921 tgcaggctgt caaccaccag atccataatag gttgtttctt gagacctttt attcccgggaa
1981 gctcagagcc tgaagctctg gtgttagaaatc ctcttcata agatctgtcg gcagccccca
2041 gcccggccca tctgtccacg tgcgtccctc ctcttagatcc ctttcctcacc tgccctgtt
2101 caagctgttt cacagctgtt accctctgtc ggctccctctt agaccacccc accccggact
2161 ctacacccatc ctgcaatggg ttccacccctc ctgaacacac ctgggtctctt ggaatggact
2221 ttggccatgc ggctccatct tcacctgggt aaccttccctc tgcaggaggc cccctgtt
2281 tggcaacct gcttgcatt ggctctccg gggagtgccc taccgggtg gttaccctgg
2341 gcaccctggg acgatggct tgcgttgc tgcacatgtt ctggcccttc tcctccatca
2401 gatccctttaga ctctttttt ttttttttgg agatggagtc ttgcgtctgtc actcaggctg
2461 gagtgcaatg gtgcgtatcc ggctcaatcc aacctctgccc tcctgggttc aagtgtattct
2521 cctgcctcag cctcccaatg agctgggatt acagacgtgt gccacaatgc ccccttatt
2581 ttttgcattttt ttagtagaga tggggcttca ccattttggc caggctggc ttgaactct
2641 gacctcaatg gattcacctc ttgcgttgc ccaaaatgtt gggattacag gcatgagct
2701 gggcccgat atttagactc ttatataatga ctgcatttttctt ggtgtctctt

FIGURE 9

(page 2 of 2)

2761 cacctggcac agtgctggc ttttgcctatg ctagctcccc cttctctatgc acacaaatgg
2821 tgctcagtaa atatttatgt attgagtaaa attaataat catttgcattga aattaaaaag
2881 tgaataaaata agttacctag aaagatgcaa agtccacaaa cctggggcac cttgcatttt
2941 ccctgagcgt aatgtttgca catcaggatg tgaggaccac gtctccctct catgtcctga
3001 gggtttata tccgcctcac tggacagttt ctgatgtcat tggagaaggaa agctgatgg
3061 gtgtgtcat gataacatca aggaattcag cccacaactt actttgcattc ttacctgtgc
3121 actttcagag acgtgtacag tggccccccg taaaagacag aattgtgggtt ttccctgggt
3181 caegccctcc cagtgtgcaa ataagggtctt ctgttcgac gacaccgttc gtggggtccc
3241 ctgggtcttc tatcctaata ccatcgacgt ccctccagaa ggtatggctt ttttatacga
3301 tgggttctga agatttagaa ttagtttagaa aagtcattt aagactacaga ggctctgatc
3361 agcatcacca gctatgcct tacacagagt cacggccgccc agtgggtgggt caatggggta
3421 gcctgagtca ggctgcattc aggtccagga atagaaaggc aagggtctaagg gactttggaa
3481 gaaacctgtat ttccccccgg ctctcttca catctctaacc caaaaggcctg ggaagagccca
3541 ctgttggtaa cgcttcttag ctgccttagg atagaggggg aaggcatgac gaaatctgaa
3601 gacatttcat gtattcttt tttttttttt ttttggaaat ggagtctcgc tccgttgc
3661 ctgagctgga gtgcaatggt gcgatcttgg ctcaactgcaa tctctgcctc ctgaggtaaa
3721 cctcagcttc cttagtagctg agattacagg tttgtgcac tacgcccagc taaatttttt
3781 ttgtatTTTT agtataagacg gggtttcacc atgttggcca gaccggctt gaactcttga
3841 cctcaggtga tctgcggcc tcagcctccc agagagctgg gattacagggc gtgagccacc
3901 gtgccccggct gacaggatcat gttttctaaa gaatgtgcct atggatactt taaagaaaa
3961 actctgtataat tgttttaatg tgaaagaaaaa tgtttacccct cactaaagca tctcttctc
4021 cctcccccttc acccctgttag aggagtgtga attttagaca cttctgcagg gatctgcctg
4081 catcctgacg cggtgccgtc cccagcacgg tgattagtcc cagagctgg ctgccaccc
4141 caccggacac ctcagacacg cttctgcagg tttgcctcgg ctcacaacac agattgactg
4201 ctctgacttt gactactcaa aattggccta aaaataaaaa gagatcgata tt

SEQUENCE LISTING

<110> The General Hospital Corporation

<120> Methods and Compositions for Treating
Oral and Esophageal Lesions

<130> 50206/002WO2

<150> US 60/286,240

<151> 2001-04-24

<160> 9

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 73

<212> PRT

<213> Homo sapien

<400> 1

Met Leu Gly Leu Val Leu Ala Leu Leu Ser Ser Ser Ser Ala Glu Glu
1 5 10 15
Tyr Val Gly Leu Ser Ala Asn Gln Cys Ala Val Pro Ala Lys Asp Arg
20 25 30
Val Asp Cys Gly Tyr Pro His Val Thr Pro Lys Glu Cys Asn Asn Arg
35 40 45
Gly Cys Cys Phe Asp Ser Arg Ile Pro Gly Val Pro Trp Cys Phe Lys
50 55 60
Pro Leu Gln Glu Ala Glu Cys Thr Phe
65 70

<210> 2

<211> 84

<212> PRT

<213> Homo sapien

<400> 2

Met Ala Thr Met Glu Asn Lys Val Ile Cys Ala Leu Val Leu Val Ser
1 5 10 15
Met Leu Ala Leu Gly Thr Leu Ala Glu Ala Gln Thr Glu Thr Cys Thr
20 25 30
Val Ala Pro Arg Glu Arg Gln Asn Cys Gly Phe Pro Gly Val Thr Pro
35 40 45
Ser Gln Cys Ala Asn Lys Gly Cys Cys Phe Asp Asp Thr Val Arg Gly
50 55 60
Val Pro Trp Cys Phe Tyr Pro Asn Thr Ile Asp Val Pro Pro Glu Glu
65 70 75 80
Glu Cys Glu Phe

<210> 3

<211> 106

<212> PRT
 <213> Homo sapien

<400> 3
 Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg
 1 5 10 15
 Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn
 20 25 30
 Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His
 35 40 45
 Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp
 50 55 60
 Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser
 65 70 75 80
 Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe
 85 90 95
 Phe Pro Asn Ser Val Glu Asp Cys His Tyr
 100 105

<210> 4
 <211> 222
 <212> DNA
 <213> Homo sapien

<400> 4
 atgctggggc tggcctggc cttgctgtcc tccagctctg ctgaggagta cgtgggcctg 60
 tctgcaaacc agtgtgccgt gccagccaag gacaggggtgg actgcggcta ccccatgtc 120
 acccccaagg agtgcaccaa ccggggctgc tgctttgact ccaggatccc tggagtgcct 180
 tggtgtttca agccctgca ggaagcagaa tgcaccccttct ga 222

<210> 5
 <211> 255
 <212> DNA
 <213> Homo sapien

<400> 5
 atggccacca tggagaacaa ggtgatctgc gccctggtcc tggtgtccat gctggccctc 60
 ggcacccctgg ccgaggccca gacagagacg tgtacagtgg ccccccgtga aagacagaat 120
 tgggttttc ctgggtgtcac gccctcccaag tgtgcaaata agggctgctg tttcgacgac 180
 accgttcgtg gggtcccctg gtgcttctat cctaataccca tcgacgtccc tccagaagag 240
 gagtgtgaat ttttag 255

<210> 6
 <211> 390
 <212> DNA
 <213> Homo sapien

<400> 6
 atgggacggc gagacgccc gctcctggca gcgcctcccg tcctgggct atgtgccctg 60
 gcggggagtg agaaaccctc cccctgcccag tgctccaggc tgagcccca taacaggacg 120
 aactgcggct tccctggaat caccagtgc cagtgttttg acaatggatg ctgtttcgac 180
 tccagtgtca ctggggtccc ctgggtttc caccctcccaag caaagcaaga gtggatcag 240
 tgcgtcatgg aggtctcaga ccgaagaaac tgtggctacc cgggcattcag ccccgaggaa 300
 tgcgcctctc ggaagtgtcg cttctccaaac ttcatcttg aagtgcctg gtgcttctc 360
 ccgaagtctg tggaaagactg ccattactaa 390

<210> 7

<211> 3280
 <212> DNA
 <213> Homo sapien

<400> 7
 atgctggggc tggctctggc cttgctgtcc tccagctctg ctgaggagta cgtgggcctg 60
 tgtgagtaact gccctgactg ccccggtggc agggtggcg tgaagggaag gatccagga 120
 taagggggga ttctgcattc attaataat ggccacctgt cacatataca cttttcctg 180
 cgctagccct ttgaagtggg tctttatgt ccccatttca cagacaagga aaccgaggct 240
 cagagaaagt taacaactta tccaaggcag ccctgcccag tctgtgtga aatcagggtt 300
 tgagcctgag cccatcccct atgacccat agccatctt gctggagatt tctaaattac 360
 aatataggtc tttatgcatt gttccacatt tacaaaagaaa aaggaaagat gcaggagaaa 420
 aaccctgact tcagaacact gtcaataccg gcaggcacaa ggttcatta gccattgcat 480
 agcaaccctg ccattgggtg tggctgtcc attaacccaa gtttgaagga atgagggcat 540
 ggcttttatac tgggtgtctt ctgagcaggg tcaaaggcag tggcccga acttgcagcc 600
 cattagaatc acctggagag cttaaaaaat cctaattgtt ggggcacacc agtacatca 660
 gggcatctcc aggcaagatc caggcctcag ctgttttgtt ttgagatagc cttgtttgt 720
 cactcactgc tggagtgcag tggcacaatc tcagctact gcaaccccg cctctgggt 780
 tcaagcaatt cttgtgcctc ggcttcaagt agctgggatt acaggcatgc accaccatgc 840
 ccagctaatt ttttgattt ttagtagaga tggagttcg ctatgttgc caagctggc 900
 tcaaactctt ggcctcaagt gatcctcctg ccttggcctc ccaaagtgtc ggaattacag 960
 gtgtaaagcca ccattggccag ccaacgtcag tcatttttaa agtctgcag ctgattccag 1020
 tgtgagcgaa gtttggatgc caggaggata agcaattacg gactgggagc aagagaaggg 1080
 aatgttaagac actgcacgtg attgcattt tccataaggaa atactcgat cgttaatgaa 1140
 acgcagtgaa cttctgtgc acatacagac atagaggctt gcctgaaaca taaaaatatt 1200
 ggggactgaa ggatgtcccg ggagggtggg acatgtctaa caattcagga agggagatg 1260
 cagaaaaaaag tgaaaagcag gcagcatgc ttgcaatgt ctctatggcg tgcctctc 1320
 ctgtcacggt tttcatttaa aacaaagggg caaggtttt tggcaaac aatgaagggt 1380
 aactttgtt ctgggttcaa gggaccccg attcccccagg ggttcctgcc agctggaagg 1440
 tacccagggtc cgtatgtac ttcccggagaa ggtgataaga gcgtgccaag gagaaagaca 1500
 cttaggccaa tgccagagt ccccgagctg agcatttaac agactgcctc tcttaataa 1560
 ttccacaggga aagtgcattc tccataaggc gagggtttca gcagtgggt aactcgccg 1620
 ggtggggcgg agcgggagga tgcaaaactt caaagtgaag caaacacact caccgcagcc 1680
 cagcaagggc tctggcagct gacagggtt tgcctggac agctgcaac cagtgcccg 1740
 tgccagccaa ggacagggtg gactgcggct acccccatgt caccggcaag gagtgcaaca 1800
 accggggctg ctgtttgac tccaggatcc ctggagtgcc tgggttcc aagccctgc 1860
 aggaaggcagg taagccccca gtggcatctg ggtctggcc cacaaggacc ccaggaagcc 1920
 tctcaggggcc tccctgtctt ttctgggtg gagatggagg cacacttagg gcagccatgg 1980
 acacacacac acctgttcca aggccctcaga gcagaggctt aaagcaattt tttcaaaaag 2040
 ccagggctg tccctttctg tcccccttta gtaaaacata gtaactattc ttgagagaag 2100
 gtgttcaaaa tgatggcattc gcatagaggg aactgtattt ctgttttgc aaatcgccc 2160
 tggaaacgca taggtgtgga aagccgggccc gacttttggg caggcgttcc cagccctaga 2220
 cccagagctc tgtcattttgt ggcattccctt acacagacgg ccccccacaag ggtcatctcc 2280
 cgtcaggcct cgggtccaca cccccacccccc cccactctgc accaccctgg gggttccctc 2340
 tctccctctc tctgcctgg tggagggcag gtgcaggcga ggcctgcac acgggtttgc 2400
 cccagggggcg gagagcctgc gtgcgtgc ggttaacagat gggccctgcac 2460
 caccctggct ccaccaggct tagctgcctt acatgtggg tggggcgatt ggctataagc 2520
 catctgcatt gtccaaagtgc cagctcagcc cccacgaagg cgcacactgc gtgaggtacc 2580
 ttccctggAAC cagcatccag agggccctt cttgcctt gtccttaggt gaaatgcggg 2640
 aggctgagtc ctgcgtggccc cggctccctg atcaatgtat ggcctgc cagggcctcc 2700
 cttcaccctc cccagcaagt ccagggttagg ggtgggggtt ggggtccaga gaaggccagg 2760
 agagagaggg gtctggctac tgcctactgc cggctctttt ccttcagtc cactggaact 2820
 acactctctt ctgagtgcca gccatggccc tgccaaaggcc catctcgctt gttatctgc 2880
 tgatccctgg gtcccaactat cttgccttagc aaccggaggt gggaaatctt gctattcccc 2940
 catgtgggtgg ggactcaaca ctccccgggtg actctggga ggaggcagca ctaggtgctg 3000
 gccttggagc ctgcctgac cttgggaagc tggcagcgt gggtggagag agactgctca 3060
 cacaaggctt tgctctgttt gcagaatgca cttctgttgc cacccttgc tgccccccgc 3120
 cggggatgc gaggctcgga gcacccttgc cggctgtga ttgcgtccagc gcactgttca 3180

tctcagctt	tctgtccctt	tgctccggc	aagcgcttct	gctgaaaagtt	cataatctgga	3240
gcctgatgtc	ttaacgaata	aaggcccatt	gctccacccg			3280
<210> 8						
<211> 4623						
<212> DNA						
<213> Homo sapien						
<400> 8						
ccccctgggg	gcagctgagc	tagacatggg	acggcgagac	gcccgactcc	tggcagcgct	60
cctcgctctg	gggctatgtg	ccctggcggg	gagtgagaaa	ccctgttaat	gaaggagagg	120
gtcttttat	gtgtttctt	tatttctt	aaagaaaaaa	aaaaagcaca	accataaatt	180
aacttgagag	ggggatggc	tataaaggca	tctggcaatg	tgtgttgc	acatggatt	240
tgccactgct	caggagggtg	gctccaagaa	gggcctccct	cctaggaaa	ggctgagtga	300
cggcagggtg	cagcgggccc	cgtgtcgccc	caggagggtc	ttcccaccaa	gggtccttgg	360
agtcccagag	cactcaccc	tcgcctgat	cttggccttg	gttccatctg	ttcacccctcc	420
tctaggaggg	ttttgtttt	gttttttcc	gagacaggat	ctggcttgc	cgcccaggca	480
ggagtgcagt	gggtgatct	tggctactg	caacctctgc	ctcccagct	caagtgtatcc	540
tcccaccca	gccgcctgag	tagctaaac	cacagttgt	gaccatcatg	cccgccaaat	600
ttttttttt	gtattgttg	tagagatggg	gtttcgacat	gttggccagg	atggtcttga	660
actcctgagc	tcaagcaatc	tgcccgctc	ggcttctaa	agtgtggaa	ttataggtat	720
gagccacca	gcctggctt	ttttttttt	tcctttaaa	ctaataaaac	aatttcagca	780
aagccctata	ggcttctcag	gaggaaaccg	cattgtttaa	atatggcaa	gataagactt	840
tgtgtttctc	tatgtggcaa	caagacagta	gaggcatccc	ctagaaccc	tgagagaagg	900
agcagtgtgg	tctgggtac	cagggtgggg	ccgactgagg	gtctttccac	agccccctgc	960
cagtgcctca	ggctgagccc	ccataaacagg	acgaactgc	gttccctgg	aatcaccagt	1020
gaccagtgtt	ttgacaatgg	atgcttttc	gactccagtg	tcactgggt	ccctgggt	1080
ttccacccccc	tcccaaagca	aggtaatctt	ccagggaaatc	ttcctggcc	agcagctggc	1140
aacccaggac	ccagcttcac	aggcggagcc	cagagcagg	gccggaggag	gccagttgc	1200
tagtctaggg	ttagcctggg	tgggttagtc	tcagactagc	cccggttgg	tagtctgggg	1260
ctagcccagg	ttggtttagtc	tagagctagc	ccaggttgg	tagtctgggg	ctagcccagg	1320
ttggtttagtc	tggggctagc	ccaggttgg	tagtctaggg	ctagtgttag	ctagttagtc	1380
taaggctagc	ccaggttgg	tagtttgag	ctagcgcagg	ttgggttagt	tggggctagt	1440
agcccagggt	ggttagcctg	gagctagccc	aggttggta	gtctaggct	agcgtaggct	1500
ggtagtctg	gggctagccc	aggttggta	gtctggagct	agcccagg	ggtagtctg	1560
gggctagtag	cccaagggtgg	ttagtcctgg	gttagccag	gttggtagt	ctagggctag	1620
tgtaggctag	ttagtctagg	gttagccag	gttagttgt	ttggagctag	cacaggttga	1680
ttagtctggg	gttagtagcc	taggttgg	agtctggagc	tagccaaat	tggtagtct	1740
agggctagca	taggtctgg	agtctggggc	tagtagcct	gttttggtag	tctggagcta	1800
gcccaagggt	gttagtctag	ggctagcgta	ggctgggtag	tctaggct	gcccaagggt	1860
gttaatcgga	gttagccag	gttggtagt	ctggagctag	cccaagggtgg	ttagtcctgag	1920
gctagtagcc	cagggtgg	agtctggggc	tagccagg	ttgttagtct	ggagctagcc	1980
cagggtgg	agtctggagc	tagcccagg	tggtagtct	gggactagcc	tggactgcta	2040
gtctagaggt	agcctagagg	actgctagtc	tagaggt	ctagggctag	cccaagggtgg	2100
ttagtctgg	gttagccat	gttggtagt	cttagactag	cctggactgc	tagtctagag	2160
gtagcccagg	ttgttagtc	tggactagc	ctggactgtt	agtctagagg	tagcccagg	2220
tggtaggtt	ggtagtctg	ggactagct	ggactgttag	tctagaggt	gcccaagggt	2280
gttagtctgg	gactagcctg	gactgttagt	ctagaggt	cccaaggatgg	ttagtcctgg	2340
actagtctgg	actgctagtc	tagaggt	ccaggttgg	tagcctgggg	ccagcctgg	2400
ctgttagtct	agaggttacc	caggcagcc	aacagtgaga	taaaaatttc	ccacccatccc	2460
tgtttctaca	ctgttagtct	tttcaacaga	catgtgtgt	tggagccatc	agtttactt	2520
tagttgagaa	aaaaatataat	atataatata	taggtcttct	ctagttttt	aagtgtact	2580
tctgaagaag	cttccatggg	gaaatgaagg	tattaatag	gacagcagta	acataagggc	2640
tgacagccct	caaatgttag	ggaaggaat	gaagccttct	agggttctt	gggagtgtat	2700
tttatgttag	tgcacgggat	caggacc	gttgcacgc	cgacgagtc	tcaaaggaag	2760
gttgtgtgt	tgtcgac	ctgtgtgcgt	ggaaccaggc	acgtccctctg	gagaaggagg	2820
attcatcccc	aagattgttg	ctggaggt	tgctggccc	cgcaggaaa	ccaggcagat	2880
ggtggattgt	tcacgagcgc	ccactgaatg	gcagtgtt	tggaaatcaa	taccatgtcc	2940

aaacgcttc catcttacca aggtgccac aaacctttc tcatcttgc cgggggacc 3000
 accccattt ctgagaacac tgagtccga gaggcaaaat gatttccca aggggggga 3060
 ctccagagct tctgactgtg accacccac atgggcccc a cttcgccga ggacaggca 3120
 gccaagcgtc gctggggccg acacttccac agtccccggg ggagggcgtc ccagggccg 3180
 acacttccac agtccccggg ggagggcgtc ccggggatg ctgccccagg cagcacctca 3240
 tgatccacgg aggctgcaaa tcagcgctgc tctcagagga ggaagggtg gagcttcca 3300
 gggcacagca ggcctgactg ggtctcggt ctgtcctgt cccatggcag agtcggatca 3360
 gtgcgtcatg gaggtcttag accgaagaaa ctgtggctac cccggcatca gcccggagga 3420
 atgcgcctct cggaaagtgtc gcttctccaa cttcatctt gaagtgcctt ggtgcttctt 3480
 cccgaagtct gtgaaaggta acgtcgctgt gggactctct gtctggttcc cggacaccat 3540
 gattcctctt ccgtccgtag aggtgggggt caggggggg agtgcctcg cagcctcagt 3600
 gccatcgagg ccaggggcccc tgcctccat gggattctga aggcaattcc agaatgttct 3660
 tggcaaagac agcgtcttt caataagtt atagcctcca gcattgcac tgcgtcatct 3720
 gtgatggctc tagaaacacgc ggctcatccc tggtccctcc ccaggtgtt caacgttcag 3780
 aggcgttgcc tggtttattt caagccatc tgcatttggaa ggctactgag tgccttgac 3840
 tgtgctgggt accagagagg gcccaactca agcagacccgt gccccttcc cctggcttc 3900
 cccgttctcc cccacatgac cccgaatgac aaacccatc cacaacgtcc tgccggggc 3960
 agtccccggg gggtcccgcc ggcagagggt aacgggtcca cttctccac ccgttagtg 4020
 atagtgtgtt cctgactcgg agtgtggcga gttaaaaaaa gaccaaggcag atccaggaaa 4080
 atggggaaag agctactggc ccttgaagga tgcctttct ttcggatattt ttaggatatac 4140
 aaagcactcc aaagagcgaat atatttcatg ttcaggattt tccgagtttgc ttttttatg 4200
 tgacctaag gtccaccttag aaaatgttca cttgtctgg gagaatgcgc cccacagagg 4260
 aaactctggc ctggggtggg aagatttggt cccttacac cccctccccg gaaaggagc 4320
 tccttcttca gttaggaagct cctggggcaaa gtgtgcacg cccaccccg ctgcagcc 4380
 taggcactcc catttctggg gttcccttac caaccatctt gcatttaaac ttctagactg 4440
 ccattactaa gagaggctgg ttccagagga tgcatttgc tcaccgggtt ttccgaaacc 4500
 aaagaagaaa ctgccttca tcagcttcat acttcatgaa atccgggtt ttcttaacca 4560
 tctttcttc atttcaatg gtttaacata taatttctt aaataaaacc cttaaaatct 4620
 gct 4623

<210> 9
 <211> 4252
 <212> DNA
 <213> Homo sapien

<400> 9
 atccctgact cggggtcgccc tttggaggcag agaggaggca atggccacca tggagaacaa 60
 ggtgatctgc gcccgttcc tgggtgtccat gctggccctc ggcacccctgg ccgaggccca 120
 gacaggtaag gcggtctct tcctgtctcg tggggccaca gccagctctg gcagcctccg 180
 ccaggagcca ctgttttaca tacatatttt tgagcacctg ttttgtgcca ggtgtgttc 240
 taggccccta aaagtatact caatttacag gatcgccaaa agcagggttga gagaactca 300
 gggtggcagg gccccccggag accttcgaga agtgcgcacgaa ggagggggct gccttcagtc 360
 ggggctgttt tcctgtgtt ggaagactat acaatcctcc caagtgtcat gtttcaaaga 420
 ggaagtgttgc gctgtgggtc tcagaatagt gcttttgcact gttcatgcca acatctcccc 480
 caggggcaga ccctcccaag gcccaccccg ataggccaa atgcccgtcc cagtgatggc 540
 cacctgggag accctctccc acagggcccgatgcccgtcc cagtggtggc caactgggag 600
 accctctctt acaggttctt gggctccctt gggatccatg ctctgggagt caaagccacc 660
 tctctcatga gtgtgtggct ggcaacccat attccctgtt gttgtcaagt ggatcggtt 720
 ccctgggtcc ttcttagggag tggaggagga ggccatttctt gcttccttgg gaagtgtttg 780
 catctcaact ccttacctg cagaatggat caacggctcg cccttagggct gtcaggaaat 840
 gctgtgtggc agcatctgcg acttgcactt tgccagctgt ggggagctga ataacttatt 900
 tgccgttatt aggtacagtt tcaagggtgg ggcaggagaa agggcttct acgtttccaa 960
 agcaagggtt tccagagagg cctgaagagg gagcgcccgatgcccgtcc cgtgccccca 1020
 ctgccttcca gccaccttctt gatctctgtc gtggggatcc gggcctgagg ggtgggtttg 1080
 ggcagcgtag aagagcagcc agcattggc tgcagtggtt gaccccccacca gccatggca 1140
 gggagcgggg gagctttggaa acccgagagaa ggaagtggcc tgggtgtaca gaacgaactg 1200
 ggtgggtccc cgtgtggcc acccccccaggc ccatttgcctt ggcgccttgc cccacccca 1260
 gcccccaagct ctgccttccgt tgctgtggaa tcacagaggc cgtggcaaac tccctcccc 1320

accccacaca ccctctggct caaggctcag agcgttttgcgggtcaactc aggtccatga 1380
 tcctgttaca actgaatct agaaaattgt gattacagtt tagtgcattc gtgtgtggaa 1440
 accatttcca tttatttcca tcatgcgaca aagacaaagc gggtgggcaa gacagagtct 1500
 gccggaggca gagcaccggg gctggaaatc ttcctccctg aggagggaaac ccccccggacc 1560
 cccaggatga tgatctccctc tcaccacggg gcctctcttgc acccccacag tgcgggggg 1620
 gtgggcgtat atcacctca cgtcgcatg gatccagacc ccaggaggc aagttccca 1680
 tggaaagctgc tgggcagcgg gagctgaaca cggatccttc ccagcaagcc aggaacactt 1740
 tctccaaaga catctcgagg cagtcctga tagcaaagca gacaagagaa cagccctct 1800
 cggcctcccc tggggcgccc tcacctgagc cagtgtggcc agactgagtt cttccctcc 1860
 tatgccccaa ggcaggagca gggaccggag ggtgctctgg gtcctcttgc acccccctgc 1920
 tgcaggctgt caaccaccag atcctaatacg tttgtcttgc gagaccttgc 1980
 gctcagagcc tgaagctctg gtgttagaac ctcttcata agatcctcg gcagccccca 2040
 gcccggccca tctgtccacg tgccttcctc ctcttagatcc ctttcctc acgcctgtctt 2100
 caagctgtt cacagcttgtt accctctgtc ggctcctcttgc accaccaccc acccggtct 2160
 ctcacccatc ctgcaatggg tttccaccc tcgaacacac ctgggtctctt ggaatggct 2220
 ttggccatgc ggctccatct tcacctgggt aacccctcc tcagggagc cccctgtctt 2280
 tggtcaacct gcttgcatt ggcctctccg gggagtggcc taccgggtgt gttaccctgg 2340
 gcaccctggg acgatggcc tgcgttgc tgcacatgtt cttgccttc tcctccatca 2400
 gatccttaga ctctttttt ttttttttgc agatggagtc ttgcctgtc actcaggctg 2460
 gagtgcaatg gtgcgtatctt ggctcaatc aaccccttc tcctgggttca aagtgtattt 2520
 cctgcctcag cctcccaagt agctgggattt acagacgtgt gccacaatgc cccgctaatt 2580
 ttttgcattt ttagtagaga tggggctca ccattttgtt caggctggtc ttgaactctt 2640
 gacctaagt gattcaccc tcctcagcctc cccaaatgtt gggattacag gcatgagct 2700
 gggcccccagat atttagactt ttatataatgc ctttcgttgc tttaattttt ggggtctctt 2760
 cacctggcacttggc ttttgcattt ctgcgtccca cttctcatgc acacaaatgg 2820
 tgctcgtatataattttatgtt atttagataaa atttaataat catttgcatttga aataaaaaaag 2880
 tgaataaaata agttaccttag aaagatgcaaa agtccacaaa cttggggcac cttgcattttt 2940
 ccctgagcgt aatgtttgc aatccatgc catcaggatg tgaggaccac gtctcccttc catgtcctga 3000
 gggttttata tccgcctcacttggacagggtt ctgcatttgc tggagaagga agctggatgg 3060
 gtgtgtgcataataacatca aggaatttcg cccacaactt actttgcctt ttacctgtc 3120
 actttcagag acgtgtacag tggccccccg taaaagacag aattgtgtt ttcttgcgtt 3180
 cacggccctcc cagtcgtcaataaagggttgcataaagggttgcacttgc gacaccgtt gttgggtccc 3240
 ctggtgcttc tatttcaataa ttagtttagaa aagtcatatc tacacagatg cttgcatttgc tttatatacg 3300
 agcatcacca gctatgcctt gatattttt tttttttttt tttttgttgc ggttgcatttgc 3360
 gcctgagtc ggtgcatttgc aggtccaggatataaagggttgcacttgc gacaccgtt gttgggtccc 3420
 gaaacctgat ttccccccggc tttcttgcatac catctctaa ctttccttc catctctaa ctttccttc catctctaa ctttccttc 3480
 ctgttggtaa cgcttcttag tttttttttt tttttgttgc ggttgcatttgc tttatatacg 3540
 gacatttcat gtattttt tttttttttt tttttgttgc ggttgcatttgc tttatatacg 3600
 ctgagcttgc gttcaatggt ggcatttttttgc tttttttttt tttttgttgc ggttgcatttgc tttatatacg 3660
 ctttcagcttc ctgttagctt gatatttttgc tttttttttt tttttgttgc ggttgcatttgc tttatatacg 3720
 ttgttattttt agtataagacg gggtttccacc tttttttttt tttttgttgc ggttgcatttgc tttatatacg 3780
 ctttcaggtga tctggccggcc tttttttttt tttttgttgc ggttgcatttgc tttatatacg 3840
 gtggccggct gacagttcat tttttttttt tttttgttgc ggttgcatttgc tttatatacg 3900
 actctgtat tttttttttt tttttttttt tttttgttgc ggttgcatttgc tttatatacg 3960
 ctttccttc acccctgttag aggtgttgc tttttttttt tttttgttgc ggttgcatttgc tttatatacg 4020
 catcctgacg cggtggccgtc cccagcacgg tttttttttt tttttgttgc ggttgcatttgc tttatatacg 4080
 caccggacac ctcagacacgc tttttttttt tttttgttgc ggttgcatttgc tttatatacg 4140
 ctctgacttt gactactcaa aattggccta aaaaattaaaaa gagatgcata tt 4200
 ctctgacttt gactactcaa aattggccta aaaaattaaaaa gagatgcata tt 4252

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/12891

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/00, 38/16
US CL : 514/2, 12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514/2, 12; 435/69.1, 91, 172.3, 320.1, 235.1; 536/27, 23.5; 530/300; 935/9, 10, 23

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,E	US 6,221,840 B1 (PODOLSKY et al) 24 April 2001 (24.04.2001), abstract, column 1, lines 25-38, column 15, lines 33-47, column 16, lines 1-5, column 27 lines 14-35, column 28, lines 13-34.	1-6, 34-38, 42
X	US 6,063,755 A (PODOLSKY et al) 16 May 2000 (16.05.2000), abstract, column 1, lines 29-33, column 3, lines 61-67, column 9, lines 31-34, column 10, lines 1-3.	1-16, 34-38, 42
A	MODLIN et al. Trefoil Peptides: Mitogens, Motogens, or Mirages? J. Clin. Gastroenterol. 1997, Vol.25 (Suppl. 1), pages S94-S100.	1-7, 10-16

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 30 July 2002 (30.07.2002)	Date of mailing of the international search report 11 SEP 2002
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized Officer B. Dell Chism Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/12891

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-55 (in-part)

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

1. This International Preliminary Examining Authority has found greater than 1 invention claimed in the International Application covered by the claims indicated below:

This application contains more than one invention or group of inventions wherein the inventions or group of inventions consists of a method and a product:

Group I, claim(s) 1-55, drawn to methods of treatment by trefoil peptide and a second therapeutic and the composition for such treatment.

However, the first invention claims a method of treatment requiring a trefoil peptide and subsequently claims three peptides of similar function but are structurally different for use in the treatment scheme. One or more of the peptides is/are known in the art (i.e. intestinal trefoil factors) (U.S. Patent No. 6,063,755) and therefore lack a special technical feature. Applicant must elect one peptide of the three. Additionally, the first invention claims a second therapeutic for use in conjunction with one of the structurally different peptides, however, the applicant claims six different classes of compounds to represent the second therapeutic wherein the classes are further divided into subgroups of therapeutics. The applicant must elect one representative for the second therapeutic. Furthermore, the first invention claims formulations for the peptide and the second therapeutic as being the same or different. The applicant needs to elect one formulation as same or different one from the other. For explanation of possible combinations see below:

1. Trefoil peptides: [A] spasmolytic polypeptide; [B] pS2; [C] intestinal trefoil factor. Applicant will receive search for [A] or Applicant must pay additional for either or both [B] and [C].
2. Second Therapeutic:
 - a. anti-inflammatory;
 - b. Antibacterial agent; (i) penicillin, (ii) cephalosporin, (iii) tetracycline, (iv) aminoglycoside, or (v) povidone-iodine.
 - c. anti-fungal agent; (i) nystatin or (ii) Amphotericin B.
 - d. anti-viral agent;
 - e. analgesic; (i) lidocaine or (ii) benzocaine.
 - f. steroid; (i) triamcinolone or (ii) hydrocortisone.
3. As to each of (a) to (f), Applicant needs to elect from (a); after first member of group additional fees for each member are required.
3. Formulation:
 - a. same formulation
 - b. different formulation

As demonstrated by the itemization above, there are 78 possible combinations of methods. Additional fees are required for searches beyond the first member or each group above. If additional members are not chosen and the required fees paid for the additional members, the first member of each group only will be searched.

Continuation of B. FIELDS SEARCHED Item 3:

INTERNATIONAL SEARCH REPORT

PCT/US02/12891

STN, SCISEARCH, BIOSIS, WEST, MEDLINE, TREFOIL, INTESTINAL, PEPTIDE, FACTOR, INFLAMMATORY, BACTERIAL, FUNGAL, ANTI, VIRAL, ANALGESIC, STEROID, LESION, ALIMENTARY, INFLAMMATION